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ABSTRACT 
Using the available structural information of the chemokine receptor CXCR4, we present hit finding 
and hit exploration studies that make use of virtual fragment screening, design, synthesis and 
structure-activity relationship (SAR) studies. Fragment 2 was identified as virtual screening hit and 
used as a starting point for the exploration of 31 N-substituted piperidin-4-yl-methanamine 
derivatives to investigate and improve the interactions with the CXCR4 binding site. Additionally, 
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subtle structural ligand changes lead to distinct interactions with CXCR4 resulting in a full to partial 
displacement of CXCL12 binding and competitive and or non-competitive antagonism. Three-
dimensional quantitative structure-activity relationship (3D-QSAR) and binding model studies were 
used to identify important hydrophobic interactions that determine binding affinity and indicate key 
ligand-receptor interactions. 
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1. Introduction  
Chemokines and G protein-coupled chemokine receptors (GPCRs) play an important role in the 
immune defense system by controlling the migration, activation, differentiation, and survival of  
leukocytes.[1] Endogeneous chemokine proteins stabilize their cognate chemokine receptors in an 
active conformation that facilitates intracellular signal transduction by interactions with G proteins 
and/or arrestins.[1, 2] Because of their crucial role in the migration of immune cells, chemokine 
receptors are promising drug targets for various immune-related diseases, including chronic 
obstructive pulmonary disease, multiple sclerosis, rheumatoid arthritis, HIV-1 infection and 
cancer.[3, 4] Molecular pharmacology, medicinal chemistry and molecular modeling studies have 
provided insights into molecular determinants of chemokine receptor modulation by proteins, 
peptides, and small-molecule ligands.[1, 5] In the past few years, the first high-resolution crystal 
structures of chemokine receptors have been solved and these have given detailed structural 
information on the interaction of chemokine receptors and their ligands.[6] The crystal structures of 
vMIP bound CXCR4[7], CCL5 bound CCR5[8], and CX3CL1 bound US28[9] complexes show how 
chemokine ligands bind the N-terminal and extracellular loop regions of the receptor with their 
relatively conserved C-terminal domains and target the orthosteric seven-transmembrane helical 
domain (TMD) with their variable N-terminal regions.[5] Moreover, CCR2, CCR5 and CXCR4 
crystal structures show how small-molecule drug-like ligands (BMS-681, maraviroc, IT1t, Fig. 1) 
and medium sized peptidomimetic (CVX15) target the TMD binding site (“ancestral” orthosteric 
binding site[10]) and block the binding of the chemokine N-terminus.[6, 11, 12] Recent CCR2 and 
CCR9 crystal structures reveal that chemokine receptors may also contain a conserved intracellular 
allosteric binding site overlapping with the G protein coupling site that can be targeted by small 
drug-like ligands (CCR2-RA-[R], Vercirnon).[12-15] Despite the breakthroughs in the elucidation of 
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crystal structures of chemokine receptors, the computational prediction of receptor-ligand 
interactions to guide structure-based ligand discovery is still facing several challenges. The large, 
open and solvent accessible orthosteric TMD binding sites of chemokine receptors are challenging 
targets for structure-based virtual ligand screening[5] compared to the more druggable, occluded 
binding sites of e.g. aminergic GPCRs.[16, 17] To effectively interact with these binding sites, most 
chemokine receptor ligands are relatively large and/or hydrophobic, and contain multiple cationic 
centers to interact with conserved negatively charged residues in chemokine receptors. 
Hallmark chemokine receptor CXCR4 is activated by the endogeneous chemokine CXCL12 (also 
known as stromal cell-derived factor-1, SDF-1α) and targeted by the antagonist plerixafor/AMD3100 
(Fig. 1), the first approved drug acting on chemokine receptors and used for stem cell 
mobilization.[18] The CXCR4 receptor was the first chemokine receptor to be crystallised with 
small-molecule, peptide, and chemokine ligands and provides an ideal system to investigate the 
possibilities and limitations of structure-based ligand design.[19, 20] Chemokine receptor modeling 
studies, including the community-wide GPCR DOCK 2010 assessment to predict the three-
dimensional coordinates of the IT1t and CVX15 bound CXCR4 crystal structures, have identified 
several pitfalls associated with matching the interaction properties of chemokine receptor binding 
sites and small molecule ligands.[21] Firstly, the possibilities to translate binding mode hypotheses 
between chemokine receptors and/or ligand chemotypes is limited by: i) the symmetric distribution 
of anionic residues in the receptor (e.g. D2.63, D4.60, D6.58, E7.39 in CXCR4) and complementary 
cationic centers in known tool compounds (e.g. AMD3100, IT1t), ii) the existence of multiple 
orthosteric and allosteric small-molecule binding pockets, and iii) the ligand dependent effects of 
receptor mutation studies.[5] Secondly, the structure-based identification and optimization of 
chemokine receptor ligands is complicated by conformational sampling of larger, flexible ligands 
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and receptor binding sites as well as by defining effective scoring methods for the prioritization of 
potential ligands based on their predicted interactions with solvent accessible receptor binding 
sites.[5] Several potent small-molecule ligand classes, such as the ones exemplified by IT1t and 
AMD3100, have been identified for CXCR4 (Fig. 1)[18, 22-29] Virtual screening campaigns to 
discover novel CXCR4 ligands mostly yielded high micromolar binding affinities (IC50, Ki)[30, 31] 
or no measurable binding affinity in radiolabeled chemokine displacement studies[32, 33] and, 
considering the low ligand efficiency (delta free energy of binding divided by the number of heavy 
atoms[34]) of these hits, the potential for successful optimization was not evident. Considering the 
low LEs, it is no surprise that fragment-based approaches for peptidergic GPCRs such as chemokine 
receptors have so far been relatively scarce[5], especially when compared to other GPCRs like 
adenosine and aminergic GPCRs, for which in silico fragment screening and hit exploration was very 
successful [35, 36]. Starting point for our studies was a virtual screening hit that contains an N-
substituted piperidin-4-yl-methanamine core. Several piperidine-containing CXCR4 ligand classes 
have been reported[30, 31], including AMD3100 derivatives[37], dual CCR5/CXCR4 inhibitors[38], 
benzenesulfonamides[39] and N-substituted benzimidazoles[40]. Here we used a fragment-based 
approach that makes use of the CXCR4 structural information and molecular modelling studies to 
complement the structure-activity relationship (SAR) studies during hit exploration.  
 
 
Fig.1. Selected CXCR4 reference antagonists 
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2. Results and discussion 
2.1. Structure-based virtual screening 
We designed a structure-based virtual screening workflow focusing on the identification of small, 
fragment-like molecules[41] and customized to experimentally supported[5] CXCR4 ligand 
interaction features (HB and ionic interactions with residues D972.63 and E2887.39) (Fig. 2A). In the 
first step, a focused chemical library was prepared containing fragment-like molecules (number of 
heavy atoms ≤ 22, logP < 3, number of H-bond donors ≤ 3, number of H-bond acceptors ≤ 3, number 
of rotatable bonds ≤ 5, number of rings ≥ 1) with two basic centers, consistent with the conserved 
cationic pharmacophore features of IT1t and AMD3100 (Fig. 1) and complementary to the 
negatively charged residues D972.63, D1714.60, D2626.58, E2887.39 that have been shown to play a role 
in small-molecule ligand binding to CXCR4.[5] This focused virtual library of 52.500 fragment-like 
molecules with two cationic centers was docked in the CXCR4 crystal structure (PDB ID: 3ODU)[6] 
using GOLD[42] and PLANTS[43] docking algorithms. Molecules that were able to simultaneously 
form H-bond and ionic interactions with D972.63 and E2887.39 were ranked according to their GOLD 
(503 compounds) and PLANTS (1414 compounds) docking scores, as well as their structural 
Interaction FingerPrint (IFP)[44] compared to the co-crystallized IT1t reference (Fig. 2B). The 
docking poses of the top 200 ranked molecules were visually inspected, and molecules with polar 
groups docked in the previously identified hydrophobic hot spot between W942.60 and Y1163.33 were 
discarded.[45] A structural novelty filter (ECFP-4< 0.4[46] as compared with any known CXCR4 
ligands) resulted in a final selection of 34 fragment-like compounds, of which 23 commercially 
available compounds (specified in Fig. S1) were purchased and validated in 125I-CXCL12 binding 
studies. 
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Tested at 63 µM, four hits (1-4) showed more than 50% inhibition of 125I-CXCL12 binding to 
HEK293T cell membranes transiently overexpressing human CXCR4 (Fig. 2C) and these were 
selected for further evaluation. Fragments 2 and 3 share the same benzylpiperidin-4-yl-methanamine 
scaffold and fragment 3 was therefore discarded from further validation. Fragment hit 4 holds a 
chiral center and can potentially form a reactive quinone moiety and further fragment growing from 
this fragment was therefore deprioritized. The two remaining hits 1 and 2 were subsequently tested 
for concentration-dependent inhibition of 125I-CXCL12 binding to hCXCR4 (IC50, Table 1), resulting 
in a better pIC50 value (5.0) for fragment 2 than for 1. 
 
 
 
Fig. 2. Overview of the structure-based (SB) ligand virtual screen and design (A-G).  
(A) Overview of the different steps in the SB virtual screening work flow. (B) Compound IT1t 
(green stick) binding to CXCR4 (yellow cartoon, PDB ID: 3ODU[6]). Key residues are shown as 
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grey sticks and protein-based (PB) hydrophobic hot spots are shown in transparent grey surface. (C) 
Single concentration (63 µM) binding studies of 23 commercially available SBVS hit analogues and 
the structures of four hits showing more than 50% inhibition of 125I-CXCL12 binding to human 
CXCR4. (D-E) Two alternative binding modes of 2 (magenta stick) binding to CXCR4. IT1t is 
shown in transparency as a reference. Key residues are shown in grey stick and PB hot spots are 
shown in transparent grey surface. (F) Comparative structural interaction fingerprint (IFP)[44] 
analysis of binding modes of IT1t and 2. The structural receptor−ligand interaction patterns are 
described by IFP bit strings encoding different interaction types between the ligand and receptor 
CXCR4 amino acid residues. (G) Schematic illustration of SAR exploration of N-substituted 
piperidin-4-yl-methanamines.  
 
Docking studies of 2 into the X-ray structure of hCXCR4 (PDB ID: 3ODU[6]) suggest two 
alternative binding modes (Fig. 2D, E), which both include ionic and H-bond interactions with 
D972.63 and E2887.39, consistent with the binding mode of IT1t in the CXCR4 crystal structure (Fig. 
2B).[6] In the binding mode 1, compound 2 accommodates its chlorinated phenyl group in the 
hydrophobic hot spot of CXCR4 between TM helices 1-3 and 7[5, 45] (Fig. 2D), whereas in binding 
mode 2 the chlorinated phenyl group is directed towards the major binding pocket of CXCR4 
between TM helices 3-7 (Fig. 2E). Structural Interaction FingerPrint (IFP) analysis[47] of IT1t and 
these two poses of compound 2 (Fig. 2F) shows shared interactions with key residues (W942.60, 
D972.63, Y1163.32 and E2887.39). The two alternative binding mode hypotheses and structural analyses 
were used to guide fragment growing studies to explore structure-activity relationships and improve 
the virtual screening hit 2. The ensuing design strategy involved substitutions of varying chemical 
nature on both amine moieties of the scaffold (Fig. 2G) 
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2.2. Chemistry 
The synthesis of the compounds based on 2 is outlined in Scheme 1. Compounds 6a,b,d-l were 
prepared in a direct one-pot reductive amination of benzaldehydes and commercially available 4-
(Boc-aminomethyl)piperidine 5a or 4-(Boc-aminoethyl)piperidine 5b (in case of 6f) in the presence 
of NaBH(OAc)3. Compound 6c was obtained by alkylation of amine 5a with 1-(chloromethyl)-2-
methylbenzene and K2CO3. Deprotection of 6a-l with HCl in dioxane, followed by a basic workup 
(except for compounds 7g and 7h, which were isolated as hydrochloride salts) provided key building 
blocks 2 and 7b-l. The final compound series 8-32 was obtained in a two-step reductive amination of 
benzaldehydes and 2, 7d,g-l via imine formation (followed by 1H NMR spectroscopy on isolated 
aliquots), following by reduction with NaBH4 in MeOH. Compounds 20, 21 and 29 retained traces of 
the benzylic alcohol (formed from the starting benzaldehyde during NaBH4 treatment) even after 
acid/base workup and crystallization as fumarate salts proved efficient to remove these impurities.  
 
Scheme 1. Synthesis of Small-Molecule CXCR4 ligandsa 
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aReagents and conditions: (a) NaBH(OAc)3, DCE, R1CHO (2-Cl-C6H4-CHO for 6f), rt, 17 h–6 d, 33–98%; for 6c: 1-
(chloromethyl)-2-methylbenzene, K2CO3, EtOH, reflux, 3h, 80%; (b) (i) 4 M HCl/dioxane, rt, 1–3 h; (ii) basic extraction, 
58–99% (7g and 7h isolated as dihydrochloride salts); (c) (i) R2CHO, anhydrous Na2SO4 , when using 7g and 7h: TEA, 
DCM, rt, 24 h–5 d; (ii) NaBH4, MeOH, rt, 3–30 min, 46–96%; for 21, 22 and 27 (iii) fumaric acid, 2-PrOH, rt, 2–24 h, 
38–52%.as fumarate salt. 
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2.3. Structure-activity relationship 
We synthesised and evaluated a variety of analogues of hit fragment 2. As depicted in table 1, the 
left-hand ring of the scaffold bearing substituent R1 and the right-hand ring with R2 substitution are 
assigned as the A-ring and B-ring, respectively. To evaluate the binding affinity, displacement assays 
were performed in which 125I-CXCL12 binding to human CXCR4 was displaced by the ligands at 
multiple concentrations (Table 1). As partial or no displacement of CXCL12 binding by small-
molecule CXCR4-binding ligands is a known phenomenon,[38] we also monitored the extent of 
displacement at 100 µM concentration of a ligand (Table 1). To assess the relative contributions of 
the different chemical modifications to CXCR4 binding affinity, we monitored the ligand efficiency 
(LE) and ligand-lipophilic efficiency (LLE) metrices (Table 1).[48] We first explored a small series 
of analogues in which the 2-chlorophenyl moiety of 2 was varied (7b-e) to evaluate the effect of the 
ring substituent R1. Comparing the SBVS hit 2 (pIC50 = 5.0) and its derivatives 7b-e (pIC50 < 5), the 
o-chlorophenyl moiety shows the best results. Elongating the chain between the piperidine and the 
NH2 group (7f) did not improve binding affinity. Considering ligand binding mode variability 
associated with the symmetric di-cationic pharmacophore[49] and chemical elaborations[50] of the 
central scaffold, we continued to probe the A-ring while appending several simple benzyl-type B-
rings (8-13). Compounds 8 and 9 failed to show good affinity (pIC50 ≤ 5), indicating the possible 
requirement for a lipophilic substitution on the A-ring. The o-methoxy analogue 10 (pIC50 = 5.6) 
gave a modest increase in affinity with respect to 8, which could be further enhanced by a m-methyl 
or m-ethyl substituent on the B-ring (11, 12). However, as observed in the analogues without B-ring, 
the affinity of o-chlorophenyl analogue 13 (pIC50 = 6.6) was superior as it was 10-fold higher than 
that for o-methoxy substituted compound 10, indicating a key overall contribution of the o-
chlorophenyl substituent to the binding affinity. Compound 13 showed full displacement of 125I-
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CXCL12 (Table 1, Fig. 3). Further exploration kept the o-chlorophenyl group in place and was 
dedicated to explore the preferred nature and substitutions of the B-ring. Replacing the phenyl B-ring 
in 13 with polar rings such as pyridine (14) or imidazole (15) resulted in reduced affinity (pIC50 = 5.7 
and 6.0, respectively). Yet, both compounds displayed relatively high (89 and 96 %) displacement of 
125I-CXCL12. The introduction of a cyclohexyl ring (16, pIC50 = 5.5) resulted in 12-fold decrease in 
affinity compared to 13. A 2,3-dichlorophenyl substituent (17) displayed lower affinity (pIC50 = 5.6) 
and a remarkable loss of maximal displacement (13%) of 125I-CXCL12 binding to hCXCR4. 
Derivatives with oxygen-based groups such as p-methoxy, m,p-methylenedioxy or p-hydroxy (18-
20) showed moderate affinity and displacement, presenting no improvement with respect to 13. 
Interestingly, the results for 20 (pIC50 = 6.5 and 98% of 125I-CXCL12 displacement) contrast sharply 
to those of 9 (with a p-OH on the A-ring), indicating possible favourable interactions involving 
hydrogen bonding in the B-ring.  
We also explored the impact of the size of the B-ring moiety by introducing a bulky naphthyl (21) or 
biphenyl (22) moiety. Both compounds showed similar affinity for CXCR4 (pIC50 = 6.3). It is noted 
that the biphenyl analogue 22 fully displaces 125I-CXCL12 binding to CXCR4 (Table 1, Fig. 3). 
Interestingly, only a selection of the compounds in table 1 show a full displacement of the chemokine 
radioligand, most notably 13, 15, 20 and 22. These ligands show reasonable diversity in the B-ring 
while other close analogues do not fully displace the radioligand. This shows that the very subtle 
pharmacological differences cannot be explained by SAR or by molecular modelling (vide infra). A 
focused positional scan of the B-ring with either a Cl- or methyl-moiety was undertaken (23-28). All 
six analogues showed slightly lower level of displacement (69-80 %) compared to the unsubstituted 
analogue 13 (95 %). The p-chloro (23) and p-methyl (24) analogues show a decrease in binding 
affinity and LLE. The o-chloro (25), o-methyl (26) and m-chloro (27) substituted analogues possess 
comparable affinities (pIC50 = 6.7, 6.6 and 6.5, respectively) to 13. Encouragingly, the m-methyl 
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analogue (28) shows a pIC50 value of 6.8 with, however, a partial displacement (63%) of 125I-
CXCL12 binding (Table 1, Fig. 3). Substitution on the meta position on the B-ring was deemed 
preferred within the o-chlorosubstituted A-ring series. To re-examine the role of the position of the 
chlorine substituent on the A-ring with a meta-methyl substituted B-ring, we synthesised positional 
analogues of 28 (29, 30) as well as selected dichloro derivatives (31, 32). The loss of affinity for the 
both m-chloro (29) and p-chloro (30) substituted analogues (pIC50 5.6 and 5.0, respectively) confirms 
an important role for the ortho substitution of chlorophenyl group. The results also revealed that a 
2,3-disubstituted dichloro analogue (31) is less potent (pIC50 = 6.1) compared to 28, whereas the 2,6-
disubstituted isomer (32) is equipotent to 28. However, both disubstituted analogues possess lower 
LLE (0.28 and 0.67) compared to 28 (LLE = 1.59) due to the increased lipophilicity.  
Table 1 
Binding affinity, level of inhibition of 125I-CXCL12 binding and efficiency metrics for SBVS 
fragment hits and improved ligands 
 
Compound R1 (A-ring) R2 (B-ring) pIC50a 
125I-CXCL12  
displacement, 
%b  
clog
P 
LE
c 
LLE
d 
CXCL12 - - 9.3 ± 0.1 97 ± 0 - - - 
AMD3100 - - 6.7 ± 0.1 98 ± 3e -0.25 
0.2
5 
6.78 
IT1t - - 8.0 ± 0.0 100 ± 2 5.39 0.4 2.61 
14 
 
2 
1 - - < 5e 70 ± 3e 3.48 
0.3
6 
0.74 
2 
 
H 5.0 ± 0.0e 69 ± 2e 2.51 
0.4
3 
2.49 
7b 
 
H < 5 67 ± 6f 3.11 
0.3
8 
1.60 
7c 
 
H < 5 81 ± 4f 2.25 
0.4
0 
2.39 
7d 
 
H < 5 67 ± 4f 1.72 
0.3
9 
3.11 
7e 
 
H < 5 59 ± 3f 2.49 
0.4
0 
1.94 
7f 
 
H < 5 56 ± 6f 3.04 
0.3
5 
1.28 
8 
  
5.0 ± 0.1 72 ± 2 3.98 
0.3
1 
1.02 
9 
  
< 5 65 ± 2f 3.31 
0.2
7 
1.17 
10 
  
5.6 ± 0.1 85 ± 1 3.89 
0.3
2 
1.74 
11 
  
6.1 ± 0.1 84 ± 3 4.39 
0.3
3 
1.67 
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12 
  
6.1 ± 0.0 81 ± 1 4.92 
0.3
2 
1.14 
13 
  
6.5 ± 0.1g 87 ± 4 4.69 
0.3
9 
1.81 
14 
  
5.7 ± 0.2 89 ± 1 3.19 
0.3
4 
2.50 
15 
  
6.0 ± 0.1 96 ± 1 2.52 
0.3
8 
3.53 
16 
  
5.5 ± 0.1 77 ± 4 5.31 
0.3
3 
0.21 
17 
  
5.6 ± 0.3 13 ± 11 5.99 
0.3
1 
-0.40 
18 
  
5.9 ± 0.1 88 ± 2 4.61 
0.3
2 
1.29 
19 
  
6.6 ± 0.2 72 ± 3 4.65 
0.3
5 
1.97 
20 
  
6.5 ± 0.2 98 ± 1 4.02 
0.3
7 
2.46 
21h 
  
6.3 ± 0.1 78 ± 1 5.86 
0.3
2 
0.40 
22h 
  
6.3 ± 0.0 98 ± 1 6.58 
0.3
0 
-0.27 
16 
 
 
a Measured as competition of 125I-CXCL12 (50 pM) binding to hCXCR4 expressed in membranes of transiently 
transfected HEK293T cells. pIC50 values are means ± SEM (N = 3 with each experiment performed in triplicate).  
b Percentage displacement of 125I-CXCL12 (50 pM) in a presence of the ligand (100 µM) relative to IT1t (100 µM, 100 
%). 
c Ligand efficiency LE = ΔG/HA = (– RT ln(IC50))/HA, where R = 8.31447215 J/(K mol), T = 298.15 K, 1 kcal = 4184 J, 
HA = number of non-hydrogen atoms in molecule.  
23 
  
6.2 ± 0.2 80 ± 4 5.40 
0.3
5 
0.81 
24 
  
6.0 ± 0.2 62 ± 1 5.19 
0.3
4 
0.82 
25 
  
6.7 ± 0.2 80 ± 4 5.40 
0.3
8 
1.31 
26 
  
6.6 ± 0.1 72 ± 5 5.14 
0.3
8 
1.50 
27h 
  
6.5 ± 0.1 65 ± 7 5.40 
0.3
7 
1.07 
28 
  
6.8 ± 0.1 63 ± 1 5.19 
0.3
9 
1.59 
29 
  
5.6 ± 0.1 86 ± 2 5.19 
0.3
2 
0.38 
30 
  
5.0 ± 0.1 86 ± 1 5.19 
0.2
8 
-0.19 
31 
  
6.1 ± 0.1 74 ± 2 5.78 
0.3
3 
0.28 
32 
 
 
6.6 ± 0.1 60 ± 3 5.90 
0.3
6 
0.67 
17 
 
d Ligand-lipophilicity efficiency LLE = pIC50 – clogP, where clogP is calculated logP value of a compound and logP is 
the logarithm of the partition coefficient of the compound between n-octanol and water log(coctanol/cwater).[51]  
e Measured as competition of 125I-CXCL12 (40 pM) binding to hCXCR4 expressed in membranes of transiently 
transfected HEK293T cells. pIC50 values are means ± SEM (N = 3 with each experiment performed in triplicate). 
Percentage displacement calculated in a presence of the ligand (63 µM) relative to IT1t (63 µM, 100 %). 
f Full inhibition could not be achieved due to pIC50 < 5. The shown value is the percentage of inhibition detected at 100 
µM. 
g pIC50 value is mean ± SEM (N = 9 with each experiment performed in triplicate). 
h Isolated and tested as fumarate salts 
 
 
Fig. 3. (A) Inhibition of 125I-CXCL12 binding to hCXCR4 expressed in HEK293T membranes by 
compounds 13, 22 and 28, and reference ligands IT1t and CXCL12. Representative curves are 
shown. Experiments were performed N ≥ 3 with each experiment performed in triplicate and mean 
values ± SEM are shown in Table 1. (B) The concentration-response curves for displacement of 
CXCL12-red binding to NLuc-tagged CXCR4 by selected ligands 13, 22 and 28. Curves are 
normalized to buffer (0%) and IT1t (100%). Experiments were performed N = 3 with each 
experiment performed in triplicate and mean values ± SEM are shown in Table S1. 
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2.4. Pharmacology of key compounds 
A concise set of key compounds (13, 22 and 28) was selected for further pharmacological analysis. 
Compound 13 displays the highest ligand efficiency (LE = 0.40) together with a good affinity (pIC50 
= 6.6) and a full displacement of 125I-CXCL12 binding to hCXCR4. o-Chloro substitution on the A-
ring together with m-phenyl (22) or m-methyl (28) substitution on the B-ring showed a positive effect 
on binding affinity (pIC50 = 6.8 and 6.3, respectively) but a remarkably different level of maximal 
125I-CXCL12 displacement (98 and 63%, respectively). Within this key set of three, the radioligand 
displacement results were found to correlate with the results obtained from complementary 
NanoBRET binding measurements for the displacement of the binding of fluorescently labelled 
CXCL12-red (25 nM) to NLuc-tagged CXCR4 by the key ligands (Fig. 3B). The binding affinities 
and the displacement (%) values are combined in Table S1.  
The different levels of 125I-CXCL12 displacement as observed for 22 and 28 indicate distinct 
interactions of the two small molecules with CXCR4. Therefore, we assessed the antagonistic 
properties of the three ligands (13, 22 and 28) and the reference antagonist AMD3100 against 
CXCL12-induced CXCR4 activation. In the presence of multiple (0-100 µM) concentrations of the 
ligand, AMD3100 and 13 (Fig. 4A, B) inhibit the CXCL12-induced G protein activation by CXCR4 
in a competitive manner, most likely indicating orthosteric interaction with CXCL12. In contrast, 
compounds 22 and 28 both show non-competitive antagonistic effects on CXCL12-induced CXCR4 
activation (Fig. 4C, D). Interestingly, in the binding study (Fig. 3A) their effect on the inhibition of 
125I-CXCL12 binding to CXCR4 differ: compound 22 fully inhibits (98%) 125I-CXCL12 binding 
(related to IT1t = 100%), whereas 28 is a partial displacer showing 63 % inhibition (Table 1). Thus, 
amongst the series of CXCR4 ligands, we have found both competitive and non-competitive 
antagonists including full and partial displacers of CXCL12 binding. 
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Fig. 4. Evaluation of the effect of key ligands on CXCR4-mediated G protein activation following 
CXCL12 binding. The concentration-response curves for CXCL12 were determined in the presence 
of various concentrations of the ligands. G protein activation was measured by pre-incubation of 
HEK293T cells with increasing concentration of a compound for 30 min followed by addition of 
CXCL12. Experiments were performed N ≥ 3 with each experiment performed in quadruplicate. (A, 
B) Competitive behavior by reference antagonist AMD3100 and compound 13. (C, D) Non-
competitive behavior of compounds 22 and 28. 
The set of key ligands together with positive control IT1t and the low-affinity ligand 9 as negative 
control were evaluated in additional functional assays (β-arrestin 2 and Inositol phosphate 
accumulation). CXCR4-mediated Gi signalling in response to 10 nM CXCL12 was redirected to the 
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phospholipase C – inositol triphosphate (InsP3) pathway by co-expression of the chimeric Gαq/i5 
protein (Fig. 5A), as previously described.[52] Key compounds 13, 22 and 28 completely inhibited 
this CXCL12 induced InsP3 formation in concentration-dependent manner with comparable pIC50 
values (Table 2). As expected, compound 9 did not significantly inhibit CXCL12-induced signalling 
in this assay. In line, key compounds 13, 22 and 28 displayed similar pIC50 values in inhibiting β-
arrestin 2 recruitment to hCXCR4 in response to 10 nM CXCL12 as measured in a BRET-based 
assay (Fig. 5B and Table 2). Compound 9 had >10-fold lower pIC50 value, which is in line with its 
lower ability to inhibit 125I-CXCL12 binding as compared to compounds 13, 22 and 28.  
Taken altogether, these results demonstrate that despite the distinct displacement of CXC12 binding 
to CXCR4 (Fig. 3A, B) and being either competitive or non-competitive antagonists (Fig. 4) of 
CXCL12 signalling via CXCR4, compounds 13, 22 and 28 can be functionally considered full 
antagonists of CXCR4 chemokine mediated signalling via both Gi proteins and β-arrestin2. 
 
 
Fig. 5. Inhibition of CXCL12-induced CXCR4 activation by selected compounds. (A) Inhibition of 
CXCL12-induced InsP3 accumulation in HEK293T cells co-expressing CXCR4 and chimeric Gαq/i5 
proteins by increasing concentration compounds. (B) Inhibition of β-arrestin2 recruitment to CXCR4 
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in HEK293T cells in response to 10 nM CXCL12 in the presence of increasing concentration 
compounds or reference IT1t. All experiments were performed N = 3 with each experiment 
performed in triplicate and mean values ± SEM are shown in Table 2. 
 
Table 2 
Affinity and functional characterization of selected compounds 
 125I-CXCL12 binding β-arrestin 2 (BRET) 
[3H]-Inositol phosphate       
accumulation (IPx) 
Compounds pIC50a % displacementb pIC50a % inhibitionb pIC50a % inhibitionb 
 9 4.5 ± 0.3 65 ± 2  < 4.5c N/Ac < 4.5c N/Ac 
 13 6.5 ± 0.1 87 ± 4  
5.4 ± 
0.0 
103 ± 1  5.7 ± 0.2 93 ± 3  
 22 6.3 ± 0.0 98 ± 1  
5.6 ± 
0.0 
102 ± 6  5.9 ± 0.1 94 ± 3  
 28 6.8 ± 0.1 63 ± 1  
5.5 ± 
0.0 
97 ± 5  6.0 ± 0.2 87 ± 5  
IT1t 8.0 ± 0.0 100 ± 2  
7.3 ± 
0.0 
100 ± 0 7.3 ± 0.0 96 ± 4  
a Results are means ± SEM (N ≥ 3 with each experiment performed in triplicate).  
b Results are expressed as percentage of inhibition of CXCL12 binding (50 pM)/signaling (10 nM) by ligand (100 µM) 
with IT1t as reference (100 % inhibition). 
c pIC50 and percentage of inhibition could not be determined. 
 
 
2.5. CXCR4 structure-based SAR map 
The experimentally determined pIC50 values were used to construct 3D-QSAR models in order to 
identify ligand-based interaction hot spots and prioritize CXCR4-ligand binding mode models (Fig. 
6). CXCR4 binding mode models of 28, based on the two initial binding modes proposed for the 
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experimentally validated virtual screening hit 2 (Fig. 2D,E) were refined by MD simulations, 
yielding two distinct ligand conformations (Fig. S2) that were used to build the 3D-QSAR models. 
Both reference ligand conformations provide templates to construct predictive 3D-QSAR models 
with similar regression and predictive squared correlation coefficients for model 1 (R2 =0.81, q2 = 
0.76, Fig. 6A) and model 2 (R2 =0.80, q2 = 0.71, Fig. 6D). Figures 6B and 6E show that both models 
are based on three hydrophobic hotspots defined by the GRID C1= probe[53, 54], including one LB 
interaction hotspot associated with chemical variations around the A-ring of 28 (LB hot spots 1.1 and 
2.1), and two hotspots associated with variations around the B-ring of 28 (LB hot spots 1.2/1.3 and 
2.2/2.3). We used the consistency between ligand-based and protein-based interaction models[49] as 
a complementary criterion to compare ligand binding mode models 1 and 2 (Figs. 6C,F). The 3D-
QSAR model based on binding mode 2 provided a better match between the ligand-based (LB) 
interaction hot spots 2.2 and 2.3 identified by the 3D-QSAR model (Fig. 6E) and the hydrophobic 
interaction hot spots identified in the receptor binding site, composed of hydrophobic residues 
W942.60, V1123.28, H1133.29 and Y1163.32 (Fig. 6F). This druggable binding site has indeed been 
postulated to involve binding of small-molecule ligands to CXCR4 and other chemokine 
receptors.[5, 45] Two exemplary compounds 13 and 22 were selected for binding mode comparison 
with co-crystallized ligand IT1t. This analysis shows that both compounds can form ionic and 
hydrogen bond interactions with key residues D972.63 and E2887.39, and can target the hydrophobic 
area. Compound 13 (Fig. 6G) lacks a methyl moiety which would be located around hot spot 2.2 and 
2.3, explaining the lower binding affinity of 13 compared to 28. However, compound 22 (Fig. 6H) 
with a hydrophobic phenyl group also shows lower affinity, which might be explained by steric 
hindrance. The described modeling method, matching ligand and protein interaction hotspots derived 
from experimentally determined SAR data and molecular interaction field analyses, has previously 
been successfully applied to the elucidation of experimentally validated structural protein-ligand 
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interactions for histamine receptors.[49] The current study demonstrates its applicability in structure-
based ligand refinement for less druggable chemokine receptors binding sites. 
 
 
Fig. 6. Details of three-dimensional quantitative structure-activity relationships (3D-QSAR) for 
Model 1 and Model 2. (A and D) Plot of predicted versus experimental values (pIC50) of Model 1 
and Model 2. (B) Alignment of 31 compounds in model 1. Compound 28 is shown in cyan stick, 
while the others are shown in grey line. The three ligand-based (LB) hot spots are shown in sphere. 
(C and F) LB 3D-QSAR model aligned with protein-based (PB) hot spots and some key residues 
(grey stick). Compound 28 is shown in (C) cyan and green (F) stick. Important binding residues are 
depicted as sticks with grey carbon atoms. Oxygen, nitrogen, and hydrogen atoms are coloured red, 
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blue and white, respectively. H-Bonds described in the text are depicted by dashed lines. (E) 
Alignment of 31 compounds in model 2. Compound 28 is shown in green stick, while the others are 
shown in grey line. The three LB hot spots are shown in spheres. (G, H) Plausible binding modes of 
compounds 13 (dark blue stick) and 22 (orange stick), respectively. Co-crystallized ligand IT1t is 
shown in transparent magenta stick. 
 
3.  Conclusions 
The current studies explore a fragment-like CXCR4 hit that was identified by virtual fragment 
screening. Ligand-based SAR studies were complemented by molecular modelling experiments, 
including docking and 3D-QSAR studies. This resulted in models that indicate key ligand-receptor 
interactions. While the models help to explain the affinity and antagonism of the ligands, the 
observed level of displacement of chemokine CXCL12 binding can so far not be explained by the 
developed ligand-receptor models, indicating the limitations of fragment-based ligand design to 
peptidergic GPCRs. 
 
4. Experimental  
4.1. Computational Methods  
 
4.1.1. Residue Numbering and Nomenclature. The Ballesteros–Weinstein residue numbering 
scheme[55] was used throughout this manuscript. For explicitly numbered residues in specific 
receptors, the UniProt residue number is given before the Ballesteros–Weinstein residue number in 
superscript (e.g., E2887.39 in CXCR4). 
4.1.2. Preparation of the Virtual Screening Database. We downloaded commercially available 
compounds from 8 trusted vendors from the ZINC8 database[56] in SMILES format and selected di-
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cationic 52.500 fragment-like compounds (number of heavy atoms ≤ 22, logP < 3, number of H-bond 
donors ≤ 3, number of H-bond acceptors ≤ 3, number of rotatable bonds ≤ 5, number of rings ³ 1) 
from this set[57, 58] using Openeye’s filter tool[59]. We selected di-cationic compounds based on 
the experimentally supported binding mode hypothesis that ionic interactions with residues D972.63 
and E2887.39 play an important role in CXCR4 binding. The major protonation states of small 
molecules were computed with ChemAxon Calculators[60] at pH 7.4 and converted to Mol2 format 
with Molecular Networks’ CORINA.[61] 
4.1.3. Automated Docking. CXCR4 crystal structure (PDB.: 3ODU) was prepared for docking 
simulations using the MOE[62] Protonate3D module in order to ensure a plausible ionization state 
for each residue, followed by visual inspection. Docking experiments were performed with the 
programs GOLD[42] and PLANTS,[43] using the crystal structure of CXCR4 (3ODU).[6] PLANTS 
combines an ant colony optimization algorithm with an empirical scoring function[63] for the 
prediction and scoring of binding poses in a protein structure. GOLD is an automated ligand docking 
program that uses a genetic algorithm to explore the full range of ligand conformational flexibilities 
with partial flexibility of the protein. For each compound, 15 poses were calculated, and scored by 
the ChemPLP scoring function at speed setting 2 in PLANTS. All other options of PLANTS were 
left at their default setting. We performed 15 GA runs for each ligand in GOLD and the population 
size was set to 100 (selection pressure 1.1, number of islands 3, maximum number of operation per 
ligands 3000 and niches size 2); For flags, internal H-bonds and planar trigonal nitrogen flipping 
were enabled, and restricted ligand conformational space by torsion angle distributions from CSD. 
The genetic operators (pt_crosswt = 95, allele_mutatewt = 95, migratewt = 10) and other options 
were kept as default. The docking poses were sorted by GoldScore fitness function. The binding 
pocket of CXCR4 was defined by the coordinates of the center of co-crystallized IT1t in the 3ODU 
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structure and a radius of 5 Å (which is the maximum distance from the center defined by a 5 Å radius 
around IT1t).  
4.1.4. IFP Post-processing. Structural interaction fingerprint analysis[44, 64, 65] was used for post-
processing of docking poses in structure-based virtual screening studies. The IT1t binding mode in 
the original CXCR4 X-ray structure[6] (PDB code 3ODU) was used to generate reference structural 
interaction fingerprints (IFPs) as previously described.[44] Seven different interaction types 
(hydrophobic, aromatic face-to-edge, aromatic face-to-face, H-bond acceptor, H-bond donor, 
negatively charged, and positively charged interactions) were used to define the IFP. The cavity used 
for the IFP analysis consisted of the same binding pocket used for docking, including E321.26, 
K381.32, L411.35, Y451.39, F932.59, W942.60, D972.63, A982.64, W10223.50, C1093.25, V1123.28, H1133.29, Y1163.32, 
L1203.36, D1714.60, R18345.47, I18545.49, C18645.50, D18745.51, R18845.52, Y2556.51, H2817.31, S2857.35, E2887.39, F2927.42. 
Standard IFP scoring parameters, and a Tanimoto coefficient (Tc-IFP)[44] measuring IFP similarity 
with the reference molecule pose (IT1t in the CXCR4 crystal structure 3ODU, Fig. 2B), was used to 
filter and rank the docking poses of the 52.500 fragment-like compounds in the virtual screening 
library. Only poses forming an H-bond and ionic interaction with residues D972.63 and E2887.39 were 
considered. 
4.1.5. Structure-Based Virtual Screening. The screening database was docked with PLANTS and 
GOLD, and resulting docking poses were post-processed using IFP analysis and filtered for ionic and 
H-bond interactions with D972.63 and E2887.39. IFP (Tc ≥ 0.75) and PLANTS (≤ -90) scoring cut-offs 
derived from previously GPCR structure-based virtual screening on H1R[65] were used to select a 
total of 1.917 compounds. This set was clustered and compared to known CXCR4 ligands in 
ChEMBL using ECFP-4 (extended connectivity fingerprints)[66] descriptors available in KNIME 
analytics platform[67] and compared using the Tanimoto coefficient. The docking poses of well-
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populated chemical clusters of hit molecules were visually inspected in more detail, and those 
molecules that targeted the hydrophobic hot spot in the minor binding site were prioritized. This 
yielded a final set of 34 hit molecules of which 23 were purchased and experimentally tested. 
4.1.6. MD simulations. Docking studies on compound 28 revealed two alternative binding models 
and both can target D972.63 and E2887.39 simultaneously. The two distinguished models of the hit 
compound 28 bound to CXCR4 were energy minimized for 1000 steps and used to run membrane-
embedded MD simulations in GROMACS.[68] Each system was simulated for 100 ns after an 
equilibration of 5 ns in which positional restraints were gradually relaxed in order to allow lipids to 
properly adapt around the protein and to allow water molecules to fill up receptor cavities. The 
trajectories were generated unrestrained with the parameters and conditions described elsewhere[69]. 
The parameters of the ligands were obtained using the General Amber Force Field 2 (GAFF2) and 
AM1-BCC HF/6-31G* ESP fitted atomic charges[70] were used. Potential energy, RMSD, RMSF, 
and dihedrals of the simulations were analyzed with GROMACS tools. The major protonation state 
of the 31 small molecules were computed with ChemAxon’s Calculators[60] at pH 7.4. 
4.1.7. 3D-QSAR. The two refined 3D structures of compound 28 derived from MD simulations were 
used as templates and other molecules were sketched and refined using MOE[71] as previously 
described. The MIF probes (DRY and C1=) were then calculated using the GRID package (version 
22 from Molecular Discovery).[72] The probes in a radius of 5 Å around aligned compounds were 
calculated using a grid resolution of 0.5 Å. The probes values were normalized, and probes with 
standard deviation of less than 1.0 or correlation less than 0.3 were filtered out by employing R 
statistical package (version 2.7.1).[73] The Genetic method followed by GreedyStepwise method 
from Weka 3.8 data-mining software package[74] were subsequently used to automatically select the 
important probes and generate QSAR models, with dependent variables being pIC50 of CXCR4. 
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4.2. Pharmacology 
 
4.2.1. Cell Culture. Human embryonic kidney 293T cells (HEK293T) were grown at 37 °C and 5% 
CO2 in Dulbecco’s modified Eagle medium (Gibco) supplemented with 10% fetal bovine serum 
(Bodinco), penicillin-streptomycin (Gibco).  
4.2.2. CXCR4 Membrane Preparation. CXCR4-expressing HEK293T cell membranes were prepared 
as previously described.[75] HEK293T cells (2×106) were seeded in a 10-cm dish and transfected the 
next day. The medium of the cells was refreshed using 8 mL of culture medium. 5 µg of pcDEF3-
hCXCR4 was combined with 40 µg of PEI in a total volume of 500 µL 150 mM NaCl and incubated 
for 20 minutes at room temperature. Subsequently, the DNA/PEI mix was added to the cells. Two 
days after transfection, cells were collected in ice-cold PBS and centrifuged at 1500 g for 10 min at 
4°C. Subsequently, cells were washed with PBS and centrifuged at 1500 g for 10 min at 4°C. The 
pellet was resuspended in ice-cold membrane buffer (15 mM Tris pH 7.5, 1 mM EGTA, 0.3 mM 
EDTA, 2 mM MgCl2) and homogenized by 10 strokes at 1100–1200 rpm using a teflon-glass 
homogenizer and rotor. The membranes were subjected to two freeze thaw cycles using liquid 
nitrogen and centrifuged at 40,000 g for 25 min at 4 °C. The pellet was resuspended in cold Tris-
sucrose buffer (20 mM Tris pH 7.4, 250 mM sucrose), and frozen in liquid nitrogen. Protein 
concentration was determined using a BCA protein assay kit (Thermo Fisher). 
4.2.3. 125I-CXCL12 Binding Assay. CXCR4 membranes (5 µg/well) were incubated in 96-well clear 
plates (Greiner Bio One, PS, U-bottom, clear) in binding buffer (50 mM HEPES, pH 7.4, 1 mM 
CaCl2, 5 mM MgCl2, 100 mM NaCl, and 1.0% (w/v) bovine serum albumin (BSA, fraction V)) with 
approximately 50 pM 125I-CXCL12 (PerkinElmer) in the absence or presence of unlabeled ligands 
for 2 hours at 25 °C with gentle agitation. The incubations were terminated by rapid filtration 
through Unifilter 96-well GF/C plates (PerkinElmer) presoaked with 0.5% PEI using ice-cold wash 
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buffer (binding buffer supplemented with 0.5 M NaCl) to separate free from bound radioligand. The 
filter plates were dried at 52 °C and 25 µl Microscint-O was added. Bound radioactivity was 
quantified with a MicroBeta scintillation counter (PerkinElmer). Data was analyzed using the 
GraphPad Prism 7 software. Non-linear regression curves were fitted using the “log(inhibitor) vs. 
response (three parameters)” equation. Percentage displacement of 125I-CXCL12 was calculated with 
controls present on each plate (10-5 M IT1t (Tocris) for determining non-specific binding: NS, 
vehicle treated for determining total binding: TB) following this equation: (X-NS)/(TB-NS)x100. 
4.2.4. Bioluminescence Resonance Energy Transfer (BRET) β-arrestin Recruitment Assay. 0.4 µg of 
pcDEF3-hCXCR4-RLuc (as previously described)[76] and 1.6 µg pcDEF3-β-arrestin-2-mVenus (as 
previously described)[77] plasmids were combined to 12 µg of PEI in a total volume of 250 µL 150 
mM NaCl and incubated for 20 minutes at room temperature. 1 million resuspended HEK293T cells 
were added to the DNA/PEI mix, and cells were subsequently seeded (30,000 cells per well) on 96-
well white plate (Greiner Bio One, PS, F-bottom, white). Two days after transfection, culture 
medium was substituted with Hanks’ balanced salt solution (Gibco). Next, cells were pre-incubated 
in Hanks’ balanced salt solution with increasing concentrations of compound for 60 minutes before 
stimulation with 10 nM CXCL12 and addition of 5 µM Renilla Luciferase substrate coelenterazine-h 
(Promega). After 20 minutes, RLuc (480/20 nm) and BRET (540/40 nm) signals were measured on 
the Mithras LB940 (Berthold Technologies). BRET ratios were calculated as BRET signal over 
RLuc signal, and fold over vehicle was determined using controls. 
4.2.5. Inositol Phosphate (IP) Accumulation Assay. HEK293T cells (2×106) were seeded in a 10-cm 
dish and transfected the next day. The medium of the cells was refreshed using 8 mL of culture 
medium. 5 µg of DNA including pcDEF3-CXCR4 and pcDNA1-HA-Gαq/i5[52] was combined with 40 
µg of PEI in a total volume of 500 µL 150 mM NaCl and incubated for 20 minutes at room 
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temperature. Subsequently, the DNA/PEI mix was added to the cells. The next day, cells were 
transferred to (120×103/well) a poly-L-lysine (Sigma) coated 48-wells plate and were incubated 
overnight in DMEM inositol-free medium (MP) supplemented with 1 µCi/mL [3H]-myo-inositol 
(PerkinElmer). Cells were then treated with or without a dilution range of antagonist in buffer (20 
mM HEPES, 140 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 10 mM D-(+)-Glucose, pH 
7.4) with 10 nM CXCL12 and 10 mM LiCl and 0.05% BSA for 1.5h at 37 °C. Cells were lysed and 
the accumulated inositol phosphates (InsP3) were isolated using affinity purification columns (Bio-
Rad). The amount of radiolabeled IP was determined after the addition of a scintillation fluid 
(PerkinElmer) on a Tri-Carb 2800TR (PerkinElmer). 
4.2.6. Fluorescence Resonance Energy Transfer (FRET) G protein Activation Assay. To test G 
protein activation, the previously described Gαi1 FRET-based sensor and the untagged human 
CXCR4 receptor in pcDEF3 was used.[78] The G protein sensor contains all three subunits of the G 
protein in a single plasmid: the αi1 subunit fused to mTurquoise-Δ9, the β1 subunit and the γ2 subunit 
fused to cp173Venus (pGβ1-2A-cp173Venus-Gγ2-IRES-Gαi1-mTurquoise2-Δ9). HEK293T cells 
were cultured at the University of Wuerzburg (Wuerzburg, Germany) using Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 4.5 g/l glucose, 10% (v/v) fetal calf serum, 
100 U/mL penicillin G, and 100 µg/mL streptomycin sulphate and L-glutamine (2 mM) at 37 °C and 
7% CO2. To investigate G protein activation, HEK293T cells were seeded in 100 mm plates and 
allowed to grow until the cells reached 60-65% confluency. At this stage, cells were transiently 
transfected with the Effectene transfection reagent (Qiagen), according to the manufacturer’s 
instructions. For transfection, the following DNA amounts were used per plate: 1.4 µg of CXCR4 
receptor and 3 µg of Gαi1 sensor. As a control, empty vector plasmid was used. 24 h after 
transfection, black 96 well BRAND-plates (flat bottom) were coated with 90 µL poly-D-lysine (1 
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mg/mL) for 30 minutes. Next, poly-D-lysine was aspirated and each well was washed once with 200 
µL of PBS. Transfected HEK293T cells were harvested by 2 min treatment with 1 mL trypsin 
solution and cells were resuspended in culture media and counted. Cells were seeded at a density of 
30,000 cells per well. On the day of the measurement, the medium of the cells was removed and 90 
µL of measuring buffer (140 mM NaCl, 5.4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 
pH 7.3) was added to the cells and incubated at 37 °C during 30 min. Analysis of the cells was done 
24h after seeding the cells in the 96-well plates using SynergyTM Neo2 Multi-Mode Microplate 
Reader (Biotek) with Gen5TM Data Analysis Software. During the measurement, cells were excited at 
420/50 nm (Biotek CFP-YFP Filter; 1035013) and emission was monitored at 485/20 nm and 540/25 
nm (Biotek CFP-YFP Filter; 1035043). The fluorescence was read during 5 minutes to determine the 
pre-read signal. Following the pre-read measurement, 10 µL of increasing concentrations of 
CXCL12 was added to the wells for a total assay volume of 100 µL. Fluorescence was read again 
during 20 minutes to determine the post-read signal. During measurement, cells were kept at 37 °C. 
Data were analysed using the software GraphPad Prism 6. To study the effect of the antagonists on G 
protein activation, the same procedure was applied, but modified in the following way. Before the 
measurement, the test compounds, initially dissolved in DMSO, were diluted in measuring buffer to 
reach a final assay concentration of 100 µM, 10 µM, 1 µM or 0.1 µM. Cells were pre-incubated at 37 
°C during 30 min with 90 µL of buffer containing the corresponding antagonist concentration. After 
5 min of reading, G protein activation was then stimulated as described above by adding an 
additional 10 µL solution of increasing concentrations of CXCL12 and measuring for additional 20 
min. For each antagonist, 3 to 5 repetitions were performed. To confirm that the different 
concentrations of DMSO do not affect the results, G protein activation was tested in the presence of 
0%, 0.001%, 0.01%, 0.1% and 1% of DMSO in measuring buffer. 
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4.2.7. BRET CXCL12-red Binding Assay. A pcDNA3.1 plasmid containing the Nanoluc (Nluc) - 
labeled CXCR4 receptor was created from a previously described construct by replacing the 
adenosine-A1 receptor cDNA with that encoding the human CXCR4.[79] The final construct 
encoded a fusion of sig-Nluc, a Gly-Ser linker and CXCR4 with the methionine start signal removed. 
Mixed-population HEK293G cell lines (Glosensor cAMP HEK293, from Promega) were created by 
transfecting cells with the Nluc–CXCR4 receptor construct using FuGENE® (Promega) according to 
the manufacturer's instructions and then subjecting cells to selective pressure (1 mg/mL G418) for 2–
3 weeks. HEK293G cells were maintained in Dulbecco's modified Eagle's medium (DMEM) 
containing 10% fetal calf serum (FCS) and 2 mM L-glutamine at 37 °C, 5% CO2. Membranes for 
NanoBRET binding assays were prepared from HEK293-Nluc-CXCR4 cells as previously 
described.[80] Competition NanoBRET binding assays were performed essentially as described 
previously.[80] Briefly, membranes were diluted to 10 µg protein/well in HEPES buffered saline 
solution (HBSS, 25 mM HEPES, 10 mM glucose, 146 mM NaCl, 5 mM KCl, 1 mM MgSO4, 2 mM 
sodium pyruvate, 1.3 mM CaCl2, pH 7.4) and placed in white Thermo Scientific 96-well microplates 
prior to addition of compounds. 50 nM CXCL12-red (ALMAC, Edinburgh, UK) and increasing 
concentrations of competing ligand were added simultaneously. Plates were then incubated for 2h at 
37 °C when 10 µM furimazine (Promega) was added to each well and luminescence emission 
measured after 5min using a PHERAstar FS plate reader (BMG Labtech) at room temperature. 
Filtered light emissions were measured at 460 nm (80-nm bandpass) and at > 610 nm (longpass) and 
the raw BRET ratio was calculated by dividing the > 610-nm emission by the 460-nm emission. 
 
  
33 
 
4.3. Chemistry 
 
4.3.1. Materials and methods. Commercial reagents and solvents were used without further 
purification. Dry solvents (THF, DCM) were obtained from PureSolv solvent purification system by 
Inert®. All reactions were carried out under an inert N2 atmosphere unless otherwise stated. TLC 
analyses were performed with Merck F254 Alumina Silica Plates using UV visualization or staining. 
Column purifications were carried out automatically using Isolera One Biotage® equipment. 1H and 
13C (incl. 2D-NMR) spectra were recorded on a Bruker spectrometer with operating frequency 250 
MHz, 500 MHz 600 MHz and 63 MHz, 126 MHz and 151 MHz, respectively. NMR spectra were 
calibrated according to internal references for non-deuterated solvents: CHCl3 (δH = 7.26 ppm), 
CDCl3 (δC = 77.16 ppm), DMSO (δH = 2.50), DMSO-d6 (δC = 39.52 ppm) and H2O (δH = 4.79). The 
following abbreviations were used to denote multiplicities: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, qd = 
quartet of doublets, br = broad signal, app = apparent. Systematic names for molecules according to 
IUPAC rules were generated using ChemDraw Pro 16.0. Melting trajectories for compounds 9, 20-
22 and 27 were determined using Buchi M-565 melting point apparatus with the rate of 1 oC/min.  
All HRMS spectra were recorded on Bruker microTOF-Q MS using ESI in positive ion mode. 
Unless specified otherwise, all compounds have a purity ≥ 95% that was determined using a 
Shimadzu HPLC/MS workstation with a LC-20AD pump system, SPD-M20A diode array detection 
and a LCMS-2010 EV Liquid Chromatograph Mass Spectrometer and applying either a basic or 
acidic mode. Compound purities were calculated as the percentage peak area of the analyzed 
compound by UV detection at, unless stated otherwise, 230 nm. The column used is an Xbridge C18 
5 mm column (50 mm × 4.6 mm). Basic mode: Solvent B (MeCN/10% buffer), Solvent A 
(water/10% buffer). The buffer is a 0.4% (w/v) NH4HCO3 solution in water, adjusted to pH 8.0 with 
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NH4OH. The analysis was conducted using a flow rate of 1.0 mL/ min with a total run time of 8 min 
or 12 min depending on the lipophilicity of the analyte. Acidic mode: For compounds 6b and 6f an 
acidic solvent system was used: Solvent B (MeCN/0.1% formic acid) and solvent A (water/0.1% 
formic acid), flow rate of 1.0 mL/min with a run time of 8 min. Gradient settings: For 8 min run 
(basic and acidic system): start 5% B, linear gradient to 90% B in 4.5 min, then isocratic for 1.5 min 
at 90% B, then linear gradient to 5% B in 0.5 min, then isocratic for 1.5 min at 5% B. For 12 min run 
(basic system): start 5% B, linear gradient to 90% B in 4.5 min, then 5.5 min at 90% B, then linear 
gradient to 5% B in 0.5 min, then isocratic for 1.5 min at 5% B.  
 
4.3.2. Synthesis 
4.3.2.1. General procedure A. Direct Reductive Amination 
NaBH(OAc)3 (typically 1.4 eq) was added to a solution of amine 5 (typically 1.0 eq) and aldehyde 
(typically 1.0 eq) in 1,2-dichloroethane (DCE). The mixture was stirred at rt until the conversion was 
finished as judged by TLC and LC/MS analyses. The reaction mixture was quenched with 10% 
K2CO3 aqueous solution. The product was extracted with dichloromethane (DCM) (3x). The 
combined organic layers were washed with brine (1x). Subsequently, the organic layer was dried 
with anhydrous Na2SO4. The solvent was removed in vacuo to give crude product which was 
purified by flash column chromatography. Unless mentioned otherwise, cyclohexane/5% TEA : 
EtOAc/5%TEA and a gradient flow from 100-0% to 50-50% were used. 
 
The compounds 6a,b,d-l were prepared according to the general procedure A. 
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Tert-butyl ((1-(2-chlorobenzyl)piperidin-4-yl)methyl)carbamate (6a). The general procedure A 
was followed using tert-butyl-(piperidin-4-ylmethyl)carbamate (5a) (3.210 g, 15.00 mmol), 2-
chlorobenzaldehyde (2.140 g, 15.00 mmol), NaBH(OAc)3 (4.590 g, 21.00 mmol), DCE (50 mL) and 
a reaction time of 20 h. Compound 6a was obtained as a white solid (3.980 g, 78%). 1H NMR (250 
MHz, CDCl3) δ 7.47 (d, J = 7.3 Hz, 1H), 7.33 (dd, J = 7.5, 1.8 Hz, 1H), 7.25–7.13 (m, 2H), 4.59 (s, 
1H), 3.60 (s, 2H), 3.02 (app t, J = 6.3 Hz, 2H), 2.91 (app d, J = 11.6 Hz, 2H), 2.06 (app t, J = 11.4 
Hz, 2H), 1.66 (app d, J = 12.8 Hz, 2H), 1.48–1.39 (m, 10H), 1.37–1.21 (m, 2H). ESI-MS m/z: 
339.00 [M + H]+.  
Tert-butyl ((1-(3,4-dichlorobenzyl)piperidin-4-yl)methyl)carbamate (6b). The general procedure 
A was followed using 5a (3.210 g, 15.00 mmol), 3,4-dichlorobenzaldehyde (2.760 g, 15.00 mmol), 
NaBH(OAc)3 (4.590 g, 21.00 mmol), DCE (50 mL) and a reaction time of 17 h. Compound 6b was 
obtained as a white solid (4.480 g, 78%). 1H NMR (250 MHz, CDCl3) δ 7.41 (d, J = 2.0 Hz, 1H), 
7.36 (d, J = 8.2 Hz, 1H), 7.14 (dd, J = 8.2, 2.0 Hz, 1H), 4.61 (s, 1H), 3.41 (s, 2H), 3.01 (app t, J = 
6.3 Hz, 2H), 2.83 (app d, J = 11.6 Hz, 2H), 1.93 (app t, J = 11.5 Hz, 2H), 1.74–1.60 (m, 2H), 1.53–
1.38 (m, 10H), 1.32–1.16 (m, 2H). ESI-MS m/z: 372.95 [M + H]+. 
Tert-butyl ((1-(2-methoxybenzyl)piperidin-4-yl)methyl)carbamate (6d). The general procedure A 
was followed using 5a (3.210 g, 15.00 mmol), 2-methoxybenzaldehyde (2.04 g, 15.00 mmol) and 
NaBH(OAc)3 (4.590 g, 21.00 mmol), DCE (50 mL) and a reaction time of 20 h. Compound 6d was 
obtained as a white solid (3.507 g, 71%). 1H NMR (500 MHz, CDCl3) δ 7.34 (d, J = 7.4 Hz, 1H), 
7.22 (t, J = 7.8 Hz, 1H), 6.92 (t, J = 7.4 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 4.59 (d, J = 6.3 Hz, 1H), 
3.81 (s, 3H), 3.54 (s, 2H), 3.01 (app t, J = 6.1 Hz, 2H), 2.93 (app d, J = 11.4 Hz, 2H), 2.00 (app t, J 
= 11.5 Hz, 2H), 1.64 (app d, J = 12.5 Hz, 2H), 1.48–1.39 (m, 10H), 1.32–1.26 (m, 2H). ESI-MS m/z: 
335.20 [M + H]+. 
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Tert-butyl ((1-(cyclohexylmethyl)piperidin-4-yl)methyl)carbamate (6e). The general procedure A 
was followed using 5a (0.560 g, 2.50 mmol), cyclohexanecarbaldehyde (0.290 g, 2.50 mmol) and 
NaBH(OAc)3 (0.780 g, 3.50 mmol), DCE (10 mL) and a reaction time of 3 days. Compound 6e was 
obtained as a white solid (0.82 g, 76%). 1H NMR (250 MHz, CDCl3) δ 4.60 (s, 1H), 2.99 (app t, J = 
6.1 Hz, 2H), 2.84 (app d, J = 11.7 Hz, 2H), 2.07 (d, J = 7.0 Hz, 2H), 1.88–1.56 (m, 9H), 1.43 (s, 
11H), 1.34–1.06 (m, 5H), 0.95–0.71 (m, 2H). ESI-MS m/z: 311.20 [M + H]+. 
Tert-butyl (2-(1-(2-chlorobenzyl)piperidin-4-yl)ethyl)carbamate (6f). The general procedure A 
was followed using 5b (0.300 g, 1.31 mmol), 2-chlorobenzaldehyde (0.190 g, 1.31 mmol), 
NaBH(OAc)3 (0.400 g, 1.84 mmol), DCE (5 mL) and a reaction time of 6 days. Compound 6f was 
obtained as a white solid (0.330 g, 72%). 1H NMR (250 MHz, CDCl3) δ 7.43 (dd, J = 7.4, 2.0 Hz, 
1H), 7.29 (dd, J = 7.6, 1.6 Hz, 1H), 7.22–7.07 (m, 2H), 4.68 (s, 1H), 3.54 (s, 2H), 3.10 (app q, J = 
6.7 Hz, 2H), 2.93–2.78 (m, 2H), 1.90–2.10 (m, 2H), 1.70–1.56 (m, 2H), 1.48–1.30 (m, 11H), 1.29–
1.11 (m, 3H). ESI-MS m/z: 353.00 [M + H]+. 
Tert-butyl ((1-benzylpiperidin-4-yl)methyl)carbamate (6g). The general procedure A was 
followed using 5a (1.00 g, 4.69 mmol), benzaldehyde (0.500 g, 4.69 mmol) and NaBH(OAc)3 (1.390 
g, 6.56 mmol), DCE (20 mL) and a reaction time of 48 h. Compound 6g was obtained as a white 
solid (1.400 g, 98%). 1H NMR (500 MHz, CDCl3) δ 7.32–7.26 (m, 5H), 4.59 (s, 1H), 3.50 (s, 2H), 
3.01 (app t, J = 6.4 Hz, 2H), 2.90 (app d, J = 11.0 Hz, 2H), 1.95 (app t, J = 11.7 Hz, 2H), 1.69–1.59 
(m, 2H), 1.43 (s, 10H), 1.31–1.25 (m, 2H). ESI-MS m/z: 305.20 [M + H]+. 
Tert-butyl ((1-(4-hydroxybenzyl)piperidin-4-yl)methyl)carbamate (6h). The general procedure A 
was followed using 5a (2.140 g, 10.00 mmol), 4-hydroxybenzaldehyde (1.220 g, 10.00 mmol) and 
NaBH(OAc)3 (2.970 g, 14.00 mmol), DCE (50 mL) and a reaction time of 48 h. Compound 6h was 
obtained as a yellow solid (2.42 g, 74%). 1H NMR (500 MHz, CDCl3) δ 7.05 (d, J = 7.9 Hz, 2H), 
6.58 (d, J = 8.0 Hz, 2H), 4.68 (t, J = 6.2 Hz, 1H), 3.42 (s, 2H), 3.02–2.88 (m, 4H), 2.00 (app t, J = 
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11.7 Hz, 2H), 1.66 (app d, J = 13.0 Hz, 2H), 1.54–1.37 (m, 11H), 1.31–1.25 (m, 2H). ESI-MS m/z: 
321.15 [M + H]+. 
Tert-butyl ((1-(4-chlorobenzyl)piperidin-4-yl)methyl)carbamate (6i). The general procedure A 
was followed using 5a (1.07 g, 5.00 mmol), 4-chlorobenzaldehyde (0.700 g, 5.00 mmol) and 
NaBH(OAc)3 (1.48 g, 7.00 mmol), DCE (20 mL) and a reaction time of 5 days. Compound 6i was 
obtained as a white solid (0.67 g, 40%). 1H NMR (500 MHz, CDCl3) δ 7.29–7.22 (m, 4H), 4.59 (s, 
1H), 3.43 (s, 2H), 3.01 (app t, J = 6.5 Hz, 2H), 2.85 (app d, J = 11.3 Hz, 2H), 1.92 (app t, J = 11.5 
Hz, 2H), 1.64 (app d, J = 12.9 Hz, 2H), 1.47–1.39 (m, 10H), 1.30–1.21 (m, 2H). ESI-MS m/z: 339.15 
[M + H]+. 
Tert-butyl ((1-(3-chlorobenzyl)piperidin-4-yl)methyl)carbamate (6j). The general procedure A 
was followed using 5a (1.070 g, 5.00 mmol), 3-chlorobenzaldehyde (0.700 g, 5.00 mmol) and 
NaBH(OAc)3 (1.480 g, 7.00 mmol), DCE (30 mL) and a reaction time of 48 h. Compound 6j was 
obtained as a white solid (0.690 g, 41%). 1H NMR (500 MHz, CDCl3) δ 7.32 (s, 1H), 7.25–7.17 (m, 
3H), 4.62 (s, 1H), 3.46 (s, 2H), 3.05–2.92 (m, 2H), 2.87 (app d, J = 11.1 Hz, 2H), 1.95 (app t, J = 
11.6 Hz, 2H), 1.66 (app d, J = 12.8 Hz, 2H), 1.48–1.39 (m, 10H), 1.31–1.24 (m, 2H). ESI-MS m/z: 
339.15 [M + H]+. 
Tert-butyl ((1-(2,3-dichlorobenzyl)piperidin-4-yl)methyl)carbamate (6k). The general procedure 
A was followed using 5a (2.140 g, 10.00 mmol), 2,3-dichlorobenzaldehyde (1.750 g, 10.00 mmol) 
and NaBH(OAc)3 (2.970 g, 14.00 mmol), DCE (60 mL) and a reaction time of 43 h. Compound 6k 
was obtained as a white solid (1.220 g, 33%). 1H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 7.7 Hz, 
1H), 7.34 (d, J = 7.9 Hz, 1H), 7.17 (t, J = 7.8 Hz, 1H), 4.59 (s, 1H), 3.59 (s, 2H), 3.02 (app t, J = 6.5 
Hz, 2H), 2.92–2.84 (m, 2H), 2.07 (app t, J = 2.3, 11.6 Hz, 2H), 1.70–1.64 (m, 2H), 1.51–1.39 (m, 
10H), 1.35–1.21 (m, 2H). ESI-MS m/z: 373.10 [M + H]+. 
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Tert-butyl ((1-(2,6-dichlorobenzyl)piperidin-4-yl)methyl)carbamate (6l). The general procedure 
A was followed using 5a (1.070 g, 5.00 mmol), 2,6-dichlorobenzaldehyde (0.880 g, 5.00 mmol) and 
NaBH(OAc)3 (1.480 g, 7.00 mmol), DCE (30 mL) and a reaction time of 48 h. Compound 6l was 
obtained as a white solid (0.84 g, 45%). 1H NMR (500 MHz, CDCl3) δ 7.29 (d, J = 7.9 Hz, 2H), 7.13 
(br s, 1H), 4.59 (s, 1H), 3.70 (s, 2H), 2.99 (app t, J = 6.5 Hz, 2H), 2.92 (br s, 2H), 2.17 (br s, 2H), 
1.61 (br s, 2H), 1.45–1.42 (m, 10H), 1.20 (br s, 2H). ESI-MS m/z: 373.10 [M + H]+. 
Tert-butyl ((1-(2-methylbenzyl)piperidin-4-yl)methyl)carbamate (6c). To a stirred suspension of 
5a (1.000 g, 4.67 mmol) and K2CO3 (1.289 g, 9.33 mmol) in EtOH (20 mL), 1-(chloromethyl)-2-
methylbenzene (0.657 g, 4.67 mmol) was added. The mixture was heated to reflux for 3 h and then 
cooled to room temperature. Water (40 mL) was added to the reaction mixture and the product was 
extracted with DCM (3 x 40 mL). The combined organic layers were washed with brine and dried 
with anhydrous Na2SO4. The solvent was removed in vacuo to afford 6c as a white solid (1.251 g, 
80%). 1H NMR (250 MHz, CDCl3) δ 7.32–7.23 (m, 1H), 7.23–7.10 (m, 3H), 4.63 (s, 1H), 3.44 (s, 
2H), 3.02 (app t, J = 6.4 Hz, 2H), 2.89 (app d, J = 11.7 Hz, 2H), 2.36 (s, 3H), 1.98 (app t, J = 11.5 
Hz, 2H), 1.89–1.56 (m, 2H), 1.45 (s, 10H), 1.35–1.14 (m, 2H). ESI-MS m/z: 319.15 [M + H]+. 
 
4.3.2.2. General procedure B. N-Boc Deprotection 
A solution of HCl in dioxane (4 M) was added to a solution of tert-butyl ((1-benzylpiperidin-4-
yl)methyl)carbamate 6 in dioxane. The reaction mixture was stirred for 1–3 h at room temperature, 
the completion was determined by TLC. The precipitated salt was filtered and washed with EtOAc (~ 
5 mL). To this crude salt product, aqueous 10% K2CO3 solution was added to reach pH ~ 10–11. 
Extraction was performed with DCM (3x). The combined organic layers were washed with brine and 
dried with anhydrous Na2SO4. The solvent was removed in vacuo and to afford pure product after 
drying overnight in vacuo at 40 oC. 
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The compounds 2, 7b-l were prepared from the corresponding Boc-protected amines 6a-l following 
the general procedure B. Compounds 7g and 7h were isolated as hydrochloride salts.  
 
(1-(2-Chlorobenzyl)piperidin-4-yl)methanamine (2). The general procedure B was followed using 
6a (2.500 g, 7.38 mmol), dioxane (10 mL), HCl in dioxane (4 M, 10 mL) and a reaction time of 1 h. 
Compound 2 was obtained as a yellow oil (1.570 g, 89%). 1H NMR (500 MHz, CDCl3) δ 7.46 (dd, J 
= 1.7, 7.7 Hz, 1H), 7.31 (dd, J = 7.9, 1.4 Hz, 1H), 7.20 (td, J = 7.4, 1.3 Hz, 1H), 7.14 (td, J = 7.6, 
1.8 Hz, 1H), 3.58 (s, 2H), 2.96–2.86 (m, 2H), 2.56 (d, J = 5.8 Hz, 2H), 2.05 (app t, J = 11.2 Hz, 2H), 
1.75–1.63 (m, 2H), 1.31–1.19 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 136.5, 134.2, 130.63, 129.4, 
127.9, 126.6, 59.6, 53.9, 48.3, 39.4, 30.1. HR-MS m/z [M + H]+ calc. for C13H20ClN2+ 239.1310; 
found 239.1319. 
(1-(3,4-Dichlorobenzyl)piperidin-4-yl)methanamine (7b). The general procedure B was followed 
using 6b (2.500 g, 7.38 mmol), dioxane (10 mL), HCl in dioxane (4 M, 10 mL) and a reaction time 
of 1 h. Compound 7b was obtained as a yellow oil (0.640 g, 88%). 1H NMR (500 MHz, CDCl3) δ 
7.33 (d, J = 2.0 Hz, 1H), 7.26 (d, J = 8.2 Hz, 1H), 7.05 (dd, J = 8.2, 2.0 Hz, 1H), 3.31 (s, 2H), 2.74 
(app d, J = 10.8 Hz, 2H), 2.48 (d, J = 6.1 Hz, 2H), 1.84 (app t, J = 11.4 Hz, 2H), 1.63–1.56 (m, 2H), 
1.38 (s, 2H), 1.23–1.08 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 139.2, 132.0, 130.6, 130.5, 129.9, 
128.2, 62.0, 53.53, 48.0, 39.1, 29.8. HRMS-ESI m/z [M + H]+ calc. for C13H18Cl2N2+ 273.0920; 
found 273.0924. 
(1-(2-Methylbenzyl)piperidin-4-yl)methanamine (7c). The general procedure B was followed 
using 6c (0.500 g, 1.57 mmol), dioxane (4 mL), HCl in dioxane (4 M, 4 mL) and a reaction time of 1 
h. Compound 7c was obtained as a yellow oil (0.640 g, 88%). 1H NMR (250 MHz, CDCl3) δ 7.35–
7.05 (m, 4H), 3.42 (s, 2H), 2.96–2.79 (m, 2H), 2.57 (d, J = 6.0 Hz, 2H), 2.35 (s, 3H), 2.06–1.85 (m, 
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2H), 1.75–1.56 (m, 4H), 1.46–1.07 (m, 3H).13C NMR (63 MHz, CDCl3) δ 137.5, 137.1, 130.2, 129.8, 
126.9, 125.5, 61.2, 53.9, 48.2, 39.4, 30.2, 19.4. HRMS-ESI m/z [M + H]+ calc. for C14H23N2+ 
219.1861; found 219.1866. 
(1-(2-Methoxybenzyl)piperidin-4-yl)methanamine (7d). The general procedure B was followed 
using 6d (2.180 g, 6.52 mmol), dioxane (10 mL), HCl in dioxane (4 M, 10 mL) and a reaction time 
of 3 h. Compound 7d was obtained as a pale yellow oil (1.200 g, 79%). 1H NMR (500 MHz, CDCl3) 
δ 7.33 (d, J = 7.4 Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 6.91 (t, J = 7.3 Hz, 1H), 6.83 (d, J = 8.2 Hz, 
1H), 3.78 (s, 3H), 3.53 (s, 2H), 2.93 (app d, J = 10.7 Hz, 2H), 2.54 (br s, 2H), 1.99 (app t, J = 10.6 
Hz, 2H), 1.66 (app d, J = 7.7 Hz, 2H), 1.35–1.17 (m, 5H). 13C NMR (151 MHz, CDCl3) δ 157.8, 
130.5, 127.8, 126.7, 120.3, 110.4, 56.4, 55.4, 53.7, 48.26, 39.4, 30.1. HRMS-ESI m/z [M + H]+ calc. 
for C14H23N2O+ 235.1810; found 235.1795. 
(1-(Cyclohexylmethyl)piperidin-4-yl)methanamine (7e). The general procedure B was followed 
using 6e (0.400 g, 1.93 mmol), dioxane (3 mL), HCl in dioxane (4 M, 3 mL) and a reaction time of 1 
h. Compound 7e was obtained as a yellow oil (0.200 g, 74%). 1H NMR (250 MHz, CDCl3) δ 2.94 
(app d, J = 11.5 Hz, 2H), 2.63 (d, J = 5.5 Hz, 2H), 2.16 (d, J = 7.0 Hz, 2H), 2.01–1.43 (m, 13H), 
1.41–1.06 (m, 5H), 1.06–0.73 (m, 2H). 13C NMR (63 MHz, CDCl3) δ 66.3, 54.4, 48.3, 39.6, 35.4, 
32.2, 30.1, 26.9, 26.3. HRMS-ESI m/z [M + H]+ calc. for C13H27N2+ 211.2174; found 211.2178. 
2-(1-(2-Chlorobenzyl)piperidin-4-yl)ethan-1-amine (7f). The general procedure B was followed 
using 6f (0.330 g, 0.94 mmol), dioxane (2 mL), HCl in dioxane (4 M, 2 mL) and a reaction time of 1 
h. Compound 7f was obtained as a yellow oil (0.160 g, 67%). 1H NMR (500 MHz, CDCl3) δ 7.43 
(dd, J = 7.7, 1.8 Hz, 1H), 7.28 (dd, J = 7.9, 1.5 Hz, 1H), 7.17 (td, J = 7.5, 1.5 Hz, 1H), 7.11 (td, J = 
7.6, 1.8 Hz, 1H), 3.53 (s, 2H), 2.88–2.81 (m, 2H), 2.67 (t, J = 7.2 Hz, 2H), 2.00 (app t, J = 11.4 Hz, 
2H), 1.60 (app d, J = 12.6 Hz, 2H), 1.38–1.19 (m, 5H), 1.12 (br s, 2H). 13C NMR (126 MHz, CDCl3) 
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δ 136.4, 134.1, 130.5, 129.2, 127.8, 126.48, 59.6, 54.0, 40.7, 39.6, 33.3, 32.5. HRMS-ESI m/z [M + 
H]+ calc. for C14H22ClN2+ 253.1466; found 253.1471. 
(1-Benzylpiperidin-4-yl)methanamine dihydrochloride (7g). The general procedure B was 
followed using 6g (2.500 g, 8.21 mmol), dioxane (10 mL), HCl in dioxane (4 M, 15 mL) and a 
reaction time of 2 h. Basic extraction was omitted and compound 7g was obtained as the 
dihydrochloride salt (2.260 g, 99%). Due to the proton exchange with D2O, the ammonium groups 
are not visible in NMR spectra. 1H NMR (500 MHz, D2O) δ 7.55–7.34 (m, 5H), 4.26 (s, 2H), 3.60–
3.40 (m, 2H), 3.11–2.84 (m, 4H), 2.11–1.86 (m, 3H), 1.59–1.32 (m, 2H). ESI-MS m/z: 205.10 [M + 
H]+ (free amine). 
(1-Benzylpiperidin-4-yl)methanamine dihydrochloride (7h). The general procedure B was 
followed using 6h (2.000 g, 6.24 mmol), dioxane (10 mL), HCl in dioxane (4 M, 10 mL) and a 
reaction time of 3 h. Basic extraction was omitted and compound 7h was obtained as the 
dihydrochloride salt (1.770 g, 97%). Due to the proton exchange with D2O, the OH and ammonium 
groups are not visible in NMR spectra. 1H NMR (500 MHz, D2O) δ 7.33 (d, J = 8.6 Hz, 2H), 6.92 (d, 
J = 8.5 Hz, 2H), 4.19 (s, 2H), 3.52 (app d, J = 12.7 Hz, 2H), 2.98 (app t, J = 13.0 Hz, 2H), 2.92 (d, J 
= 6.8 Hz, 2H), 2.06 – 1.92 (m, 3H), 1.52–1.39 (m, 2H). ESI-MS m/z: 221.05 [M + H]+ (free amine). 
(1-(4-Chlorobenzyl)piperidin-4-yl)methanamine (7i). The general procedure B was followed using 
6i (0.580 g, 1.72 mmol), dioxane (8 mL), HCl in dioxane (4 M, 8 mL) and a reaction time of 3 h. 
Compound 7i was obtained as a yellow oil (0.300 g, 73%). 1H NMR (500 MHz, CDCl3) 7.30–7.21 
(m, 4H), 3.44 (s, 2H), 2.86 (app d, J = 11.1 Hz, 2H), 2.57 (d, J = 5.9 Hz, 2H), 1.93 (app t, J = 11.7 
Hz, 2H), 1.72–1.65 (m, 2H), 1.50 (br s, 3H), 1.27 –1.16 (m, 2H). ESI-MS m/z: 239.05 [M + H]+. 
(1-(3-Chlorobenzyl)piperidin-4-yl)methanamine (7j). The general procedure B was followed 
using 6j (0.520 g, 1.53 mmol), dioxane (5 mL), HCl in dioxane (4 M, 5 mL) and a reaction time of 3 
h. Compound 7j was obtained as a yellow oil (0.210 g, 58%). 1H NMR (500 MHz, CDCl3) 7.31 (s, 
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1H), 7.25-7.14 (m, 3H), 3.44 (s, 2H), 2.86 (app d, J = 11.7 Hz, 2H), 2.57 (d, J = 5.5 Hz, 2H), 1.93 
(app t, J = 11.5 Hz, 2H), 1.68 (app d, J = 12.0 Hz, 2H), 1.46 (br s, 2H), 1.33-1.17 (m, 3H). ESI-MS 
m/z: 239.10 [M + H]+. 
(1-(2,3-Dichlorobenzyl)piperidin-4-yl)methanamine (7k). The general procedure B was followed 
using 6k (0.490 g, 1.32 mmol), dioxane (5 mL), HCl in dioxane (4 M, 5 mL) and a reaction time of 3 
h. Compound 7k was obtained as a yellow oil (0.270 g, 74%). 1H NMR (500 MHz, CDCl3) δ 7.41 (d, 
J = 7.2 Hz, 1H), 7.34 (dt, J = 1.8, 8.1 Hz, 1H), 7.16 (td, J = 7.0, 6.2, 1.6 Hz, 1H), 3.62–3.56 (m, 
2H), 3.08 (app d, J = 6.7 Hz, 1H), 2.95–2.84 (m, 2H), 2.58 (d, J = 5.9 Hz, 1H), 2.09 (qd, J = 11.9, 
5.8 Hz, 2H), 1.80 (app d, J = 7.4 Hz, 2H), 1.78–1.62 (m, 2H), 1.31–1.23 (m, 3H). ESI-MS m/z: 
273.05 [M + H]+. 
(1-(2,6-Dichlorobenzyl)piperidin-4-yl)methanamine (7l). The general procedure B was followed 
using 6l (0.630 g, 1.70 mmol), dioxane (5 mL), HCl in dioxane (4 M, 5 mL) and a reaction time of 3 
h. Compound 7l was obtained as a yellow solid (0.340 g, 74%). 1H NMR (500 MHz, CDCl3) δ 7.28 
(d, J = 8.0 Hz, 2H), 7.11 (t, J = 8.0 Hz, 1H), 3.70 (s, 2H), 2.92 (app d, J = 11.5 Hz, 2H), 2.55 (d, J = 
6.5 Hz, 2H), 2.18 (app t, J = 11.6 Hz, 2H), 1.65 (app d, J = 13.2 Hz, 4H), 1.35–1.24 (m, 1H), 1.13–
1.22 (m, 2H). ESI-MS m/z: 273.00 [M + H]+. 
 
4.3.2.3. General procedure C. Indirect Reductive Amination 
Step I: To a mixture of (1-benzylpiperidin-4-yl)methanamine 2 or 7d,g-l (typically 1.0 eq) and 
anhydrous Na2SO4 (typically 6.0 eq) in DCM (for compounds 7h and 7g, TEA (2.0 eq) was added), 
the corresponding benzaldehyde (typically 1.0 eq) was added.. The mixture was stirred at rt until 
imine conversion was finished as judged by NMR analysis of a sample after mini-workup. The 
reaction mixture was filtered and the filtrate was evaporated in vacuo to afford the crude imine 
product.  
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Step II: The crude imine product (theoretically 1.0 eq) was dissolved in MeOH and sodium 
borohydride (NaBH4) (typically 1.4 eq) was slowly added to the reaction mixture. The mixture was 
stirred at rt until conversion was finished as judged by TLC analysis (ca. 10–30 min.). The reaction 
mixture was quenched with water (~ 2 mL) and acetone (~ 2 mL), stirred for 10 min and 
concentrated under reduced pressure. 10% K2CO3 aqueous solution was added until pH ~ 10–11, and 
the product was extracted with DCM (3x). The combined organic layers were washed with brine (1x) 
and dried with anhydrous Na2SO4. The solvent was evaporated to give crude product 8. In case of 
impurities, flash column chromatography was used for purification using cyclohexane/5%TEA : 
EtOAc/5%TEA and a gradient flow from 100-0% to 50-50%.  
 
The compounds 8–19, 22–28 and 30–32 were prepared from the corresponding amines following the 
general procedure C. Compounds 20, 21 and 29 were obtained as fumarate salts according to the 
general procedure C followed by treatment with fumaric acid. 
 
N-Benzyl-1-(1-benzylpiperidin-4-yl)methanamine (8). The general procedure C was followed 
using 7g (0.280 g, 1.00 mmol), benzaldehyde (0.110 g, 1 mmol), TEA (0.200 g, 2.00 mmol), Na2SO4 
(0.850 g, 6.00 mmol), DCM (10 mL) and a reaction time of 22 h. Imine reduction was performed 
with NaBH4 (0.053 g, 1.40 mmol), MeOH (12 mL) and reaction time of 30 min. Compound 8 was 
obtained as pale yellow oil (0.200 g, 67%). 1H NMR (500 MHz, CDCl3) δ 7.35–7.28 (m, 8H), 7.26–
7.22 (m, 2H), 3.77 (s, 2H), 3.49 (s, 2H), 2.89 (app d, J = 11.5 Hz, 2H), 2.51 (d, J = 6.8 Hz, 2H), 1.95 
(app t, J = 12.6 Hz, 2H), 1.70 (app d, J = 13.4 Hz, 3H), 1.54–1.43 (m, 1H), 1.27 (qd, J = 12.3, 3.7 
Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 140.6, 138.5, 129.4, 128.5, 128.3, 128.2, 127.1, 127.0, 63.6, 
55.5, 54.2, 53.8, 36.3, 30.6. HRMS-ESI m/z [M + H]+ calc. for C20H27N2+ 295.2174; found 295.2155. 
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4-((4-((Benzylamino)methyl)piperidin-1-yl)methyl)phenol (9). The general procedure C was 
followed using 7h (0.240 g, 0.80 mmol), benzaldehyde (0.085 g, 0.80 mmol), TEA (0.162 g, 1.60 
mmol), Na2SO4 (0.682 g, 4.80 mmol), DCM (12 mL) and a reaction time of 5 days. Imine reduction 
was performed with NaBH4 (0.042 g, 1.12 mmol), MeOH (12 mL) and reaction time of 30 min. 
Compound 9 was obtained as a yellow solid (0.11 g, 46%). Mp: 83.9–93.8 oC. H NMR (500 MHz, 
CDCl3) δ 7.39–7.22 (m, 5H), 7.06 (d, J = 8.1 Hz, 2H), 6.59 (d, J = 8.0 Hz, 2H), 3.76 (s, 2H), 3.43 (s, 
2H), 3.24–2.82 (m, 4H), 2.51 (d, J = 6.5 Hz, 2H), 1.98 (app t, J = 11.0 Hz, 2H), 1.71 (app d, J = 
12.2 Hz, 2H), 1.59–1.45 (m, 1H), 1.30 (qd, J = 12.1, 3.7 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 
156.0, 140.1, 131.2, 128.6, 128.3, 128.1, 127.2, 115.6, 62.88, 55.1, 54.2, 53.3, 36.0, 30.1. HRMS-
ESI m/z [M + H]+ calc. for C20H27N2O+ 311.2123; found 325.2270. 
N-benzyl-1-(1-(2-methoxybenzyl)piperidin-4-yl)methanamine (10). The general procedure C was 
followed using 7d (0.234 g, 1.00 mmol), benzaldehyde (0.106 g, 1.00 mmol), Na2SO4 (0.850 g, 6.00 
mmol), DCM (12 mL) and a reaction time of 42 h. Imine reduction was performed with NaBH4 
(0.053 g, 1.40 mmol), MeOH (12 mL) and reaction time of 15 min. Compound 10 was obtained as a 
colorless oil (0.15 g, 47%).1H NMR (500 MHz, CDCl3) δ 7.37–7.29 (m, 5H), 7.25–7.20 (m, 2H), 
6.93 (t, J = 7.4 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 3.81 (s, 3H), 3.77 (s, 2H), 3.54 (s, 2H), 2.94 (app 
d, J = 11.5 Hz, 2H), 2.51 (d, J = 6.7 Hz, 2H), 2.01 (app t, J = 11.2 Hz, 2H), 1.70 (app d, J = 12.5 
Hz, 2H), 1.54–1.43 (m, 1H), 1.29 (qd, J = 12.2, 3.7 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 157.9, 
140.7, 130.6, 128.5, 128.2, 128.0, 127.0, 126.7, 120.4, 110.5, 56.5, 55.6, 54.2, 53.8, 30.7. HRMS-
ESI m/z [M + H]+ calc. for C21H29N2O+ 325.2280; found 325.2270.  
1-(1-(2-Methoxybenzyl)piperidin-4-yl)-N-(3-methylbenzyl)methanamine (11). The general 
procedure C was followed using 7d (0.230 g, 1.00 mmol) and 3-methylbenzaldehyde (0.120 g, 1.00 
mmol), ), Na2SO4 (0.850 g, 6.00 mmol), DCM (12 mL) and a reaction time of 52 h. Imine reduction 
was performed with NaBH4 (0.053 g, 1.40 mmol), MeOH (12 mL) and reaction time of 20 min. 
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Compound 11 was obtained as a colourless oil (0.28 g, 82%).1H NMR (500 MHz, CDCl3) δ 7.38 (d, 
J = 7.3 Hz, 1H), 7.25–7.17 (m, 2H), 7.13 (s, 1H), 7.10 (d, J = 7.5 Hz, 1H), 7.06 (d, J = 7.4 Hz, 1H), 
6.94 (t, J = 7.4 Hz, 1H), 6.87 (d, J = 8.2 Hz, 1H), 3.81 (s, 3H), 3.73 (s, 2H), 3.61 (s, 2H), 2.99 (app 
d, J = 11.2 Hz, 2H), 2.51 (d, J = 6.7 Hz, 2H), 2.34 (s, 3H), 2.08 (app t, J = 11.5 Hz, 2H), 1.72 (app 
d, J = 12.8 Hz, 2H), 1.56–1.45 (m, 1H), 1.42–1.30 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 157.9, 
140.1, 138.1, 130.9, 129.0, 128.4, 128.2, 127.8, 125.8, 125.2, 120.4, 110.5, 56.2, 55.5, 55.3, 54.1, 
53.5, 35.9, 30.4, 21.5. HRMS-ESI m/z [M + H]+ calc. for C22H31N2O+ 339.2436; found 339.2422.  
N-(3-Ethylbenzyl)-1-(1-(2-methoxybenzyl)piperidin-4-yl)methanamine (12). The general 
procedure C was followed using 7d (0.120 g, 0.50 mmol) and 3-ethylbenzaldehyde (0.067 g, 0.50 
mmol), Na2SO4 (0.426 g, 3.00 mmol), DCM (8 mL) and a reaction time of 4 days. Imine reduction 
was performed with NaBH4 (0.026 g, 0.70 mmol), MeOH (8 mL) and reaction time of 30 min. 
Compound 12 was obtained as a colorless oil (0.093 g, 53%). 1H NMR (500 MHz, CDCl3) δ 7.37 (d, 
J = 7.2 Hz, 1H), 7.25–7.20 (m, 2H), 7.15 (s, 1H), 7.10 (dd, J = 17.8, 7.6 Hz, 2H), 6.94 (t, J = 7.4 Hz, 
1H), 6.86 (d, J = 8.1 Hz, 1H), 3.82 (s, 3H), 3.75 (s, 2H), 3.57 (s, 2H), 2.96 (app d, J = 12.0 Hz, 2H), 
2.64 (q, J = 7.6 Hz, 2H), 2.53 (d, J = 6.7 Hz, 2H), 2.04 (app t, J = 11.3 Hz, 2H), 1.71 (app d, J = 
12.4 Hz, 2H), 1.56–1.45 (m, 1H), 1.32 (qd, J = 12.2 3.7 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 157.9, 144.5, 140.5, 130.8, 128.4, 128.1, 127.7, 126.5, 126.3, 125.5, 120.4, 
110.5, 56.4, 55.6, 55.5, 54.3, 53.7, 36.1, 30.6, 28.9, 15.8. HRMS-ESI m/z [M + H]+ calc. for 
C22H33N2O+ 353.2593; found 353.2586.  
N-Benzyl-1-(1-(2-chlorobenzyl)piperidin-4-yl)methanamine (13). The general procedure C was 
followed using 2 (0.210 g, 0.87 mmol) and benzaldehyde (0.089 g, 0.83 mmol), Na2SO4 (0.710 g, 
5.00 mmol), DCM (10 mL) and a reaction time of 27 h. Imine reduction was performed with NaBH4 
(0.047 g, 1.24 mmol), MeOH (10 mL) and reaction time of 30 min. Compound 13 was obtained as a 
yellow oil (0.20 g, 75%). 1H NMR (500 MHz, CDCl3) δ 7.46-7.40 (m, 1H), 7.33–7.23 (m, 5H), 7.22–
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7.14 (m, 2H), 7.13-7.08 (m, 1H), 3.73 (s, 2H), 3.54 (s, 2H), 2.85 (app d, J = 11.6 Hz, 2H), 2.47 (d, J 
= 6.8 Hz, 2H), 2.01 (app t, J = 11.7 Hz, 2H), 1.66 (app d, J = 12.5 Hz, 2H), 1.56–1.39 (m, 2H), 
1.29–1.18 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 140.6, 136.5, 134.2, 130.7, 129.4, 128.5, 128.1, 
127.9, 127.0, 126.6, 59.67, 55.5, 54.2, 53.9, 36.2, 30.8. HRMS-ESI m/z [M + H]+ calc. for 
C20H26ClN2+ 329.1779; found 329.1788. 
1-(1-(2-Chlorobenzyl)piperidin-4-yl)-N-(pyridin-3-ylmethyl)methanamine (14). The general 
procedure C was followed using 2 (0.210 g, 0.87 mmol) and nicotinaldehyde (0.091 g, 0.83 mmol), 
Na2SO4 (0.71 g, 5.00 mmol), DCM (10 mL) and a reaction time of 24 h. Imine reduction was 
performed with NaBH4 (0.047 g, 1.24 mmol), MeOH (10 mL) and reaction time of 30 min. 
Compound 14 was obtained as a yellow oil (0.200 g, 73%). 1H NMR (500 MHz, CDCl3) δ 8.55 (d, J 
= 2.1 Hz, 1H), 8.49 (dd, J = 1.7, 4.8 Hz, 1H), 7.67 (dt, J = 2.0, 7.8 Hz, 1H), 7.48 (d, J = 7.9 Hz, 
1H), 7.33 (dd, J = 7.9, 1.4 Hz, 1H), 7.25–7.20 (m, 2H), 7.16 (td, J = 7.6, 1.8 Hz, 1H), 3.79 (s, 2H), 
3.60 (s, 2H), 2.91 (app d, J = 11.5 Hz, 2H), 2.51 (d, J = 6.7 Hz, 2H), 2.08 (app t, J = 11.6 Hz, 2H), 
1.77–1.67 (m, 2H), 1.58–1.40 (m, 2H), 1.29 (app q, J = 12.0 Hz, 2H). 13C NMR (126 MHz, CDCl3) 
δ 149.8, 148.6, 136.4, 136.0, 135.8, 134.3, 130.8, 129.4, 128.1, 126.7, 123.5, 59.6, 55.5, 53.9, 51.6, 
36.3, 30.7. HRMS-ESI m/z [M + H]+ calc. for C19H25ClN3+ 330.1732; found 330.1716. 
N-((1H-Imidazol-4-yl)methyl)-1-(1-(2-chlorobenzyl)piperidin-4-yl)methanamine (15). The 
general procedure C was followed using 2 (0.240 g, 0.97 mmol) and 1H-imidazole-4-carbaldehyde 
(0.091 g, 0.93 mmol), Na2SO4 (0.790 g, 5.56 mmol), DCM (10 mL) and a reaction time of 24 h. 
Imine reduction was performed with NaBH4 (0.053 g, 1.40 mmol), MeOH (12 mL) and reaction time 
of 30 min. Compound 15 was obtained as a yellow oil (0.290 g, 96%). 1H NMR (500 MHz, CD3OD) 
δ 7.66 (d, J = 1.2 Hz, 1H), 7.47 (dd, J = 7.5, 2.0 Hz, 1H), 7.37 (dd, J = 7.7, 1.6 Hz, 1H), 7.30–7.22 
(m, 2H), 7.04 (s, 1H), 3.79 (s, 2H), 3.63 (s, 2H), 2.94 (app d, J = 12.1 Hz, 2H), 2.55 (d, J = 6.8 Hz, 
2H), 2.12 (app t, J = 11.8 Hz, 2H), 1.78–1.68 (m, 2H), 1.62–1.53 (m, 1H), 1.31–1.21 (m, 2H). 13C 
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NMR (126 MHz, CD3OD) δ 136.6, 136.5, 135.7, 132.6, 130.5, 129.7, 127.9, 60.3, 55.3, 54.5, 46.2, 
36.3, 31.1. The 13C NMR spectrum has two missing peaks. A 2D-NMR spectrum was recorded to 
prove the structure and one missing peak was identified by HSQC (Fig. S7). HRMS-ESI m/z [M + 
H]+ calc. for C17H24ClN4+ 319.1684; found 319.1685. 
1-(1-(2-Chlorobenzyl)piperidin-4-yl)-N-(cyclohexylmethyl)methanamine (16). The general 
procedure C was followed using 2 (0.180 g, 0.75 mmol) and cyclohexanecarbaldehyde (0.084 g, 0.75 
mmol), Na2SO4 (0.639 g, 4.50 mmol), DCM (12 mL) and a reaction time of 41 h. Imine reduction 
was performed with NaBH4 (0.040 g, 1.05 mmol), MeOH (12 mL) and reaction time of 30 min. 
Compound 16 was obtained as a yellow oil (0.210 g, 84%). 1H NMR (500 MHz, CDCl3) δ 7.46 (d, J 
= 7.6 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.22 (t, J = 7.5 Hz, 1H), 7.16 (t, J = 7.6 Hz, 1H), 3.58 (s, 
2H), 2.90 (app d, J = 11.2 Hz, 2H), 2.47 (d, J = 6.8 Hz, 2H), 2.42 (d, J = 6.7 Hz, 2H), 2.05 (app t, J 
= 11.4 Hz, 2H), 1.83–1.57 (m, 7H), 1.56–1.36 (m, 2H), 1.36–1.05 (m, 5H), 0.94–0.80 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 136.5, 134.3, 130.7, 129.4, 128.0, 126.6, 59.7, 56.8, 56.0, 53.9, 37.7, 
35.9, 31.5, 30.8, 26.8, 26.1. HRMS-ESI m/z [M + H]+ calc. for C20H32ClN2+ 335.2254; found 
335.2239. 
1-(1-(2-Chlorobenzyl)piperidin-4-yl)-N-(2,3-dichlorobenzyl)methanamine (17). The general 
procedure C was followed using 2 (0.143 g, 0.60 mmol) and 2,3-dichlorobenzaldehyde (0.110 g, 0.60 
mmol), Na2SO4 (0.511 g, 3.60 mmol), DCM (10 mL) and a reaction time of 22 h. Imine reduction 
was performed with NaBH4 (0.032 g, 0.84 mmol), MeOH (10 mL) and reaction time of 30 min. 
Compound 17 was obtained as a yellow oil (0.175 g, 73%). 1H NMR (500 MHz, CDCl3) δ 7.47 (d, J 
= 7.7 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 7.35–7.28 (m, 2H), 7.25–7.14 (m, 3H), 3.89 (s, 2H), 3.59 (s, 
2H), 2.91 (app d, J = 10.7 Hz, 2H), 2.50 (d, J = 6.1 Hz, 2H), 2.07 (app t, J = 11.5 Hz, 2H), 1.72 (app 
d, J = 12.6 Hz, 2H), 1.67–1.34 (m, 2H), 1.29 (app q, J = 12.1 Hz, 2H).13C NMR (151 MHz, CDCl3) 
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δ 140.4, 136.6, 134.3, 133.2, 131.9, 130.7, 129.4, 129.1, 128.1, 128.0, 127.3, 126.7, 59.7, 55.4, 53.9, 
52.2, 36.3, 30.8. HRMS-ESI m/z [M + H]+ calc. for C20H24Cl3N2+ 397.1005; found 397.0987. 
1-(1-(2-Chlorobenzyl)piperidin-4-yl)-N-(4-methoxybenzyl)methanamine (18). The general 
procedure C was followed using 2 (0.160 g, 0.65 mmol) and 4-methoxybenzaldehyde (0.088 g, 0.65 
mmol), Na2SO4 (0.554 g, 3.90 mmol), DCM (10 mL) and a reaction time of 45 h. Imine reduction 
was performed with NaBH4 (0.034 g, 0.91 mmol), MeOH (10 mL) and reaction time of 30 min 
Compound 18 was obtained as a yellow oil (0.175 g, 75%). 1H NMR (500 MHz, CDCl3) δ 7.47 (dd, 
J = 7.6, 1.7 Hz, 1H), 7.33 (dd, J = 7.9, 1.3 Hz, 1H), 7.25–7.20 (m, 3H), 7.16 (td, J = 7.6, 1.8 Hz, 
1H), 6.91–6.81 (m, 2H), 3.79 (s, 3H), 3.72 (s, 2H), 3.59 (s, 2H), 2.91 (app d, J = 11.8 Hz, 2H), 2.51 
(d, J = 6.7 Hz, 2H), 2.11–1.95 (m, 3H), 1.71 (app d, J = 12.4 Hz, 2H), 1.57–1.45 (m, 1H), 1.28 (qd, J 
= 12.1, 3.8 Hz, 2H).13C NMR (126 MHz, CDCl3) ) δ 158.7, 136.4, 134.2, 132.4, 130.7, 129.4, 129.4, 
128.0, 126.6, 113.8, 59.6, 55.3, 55.2, 53.8, 53.5, 36.1, 30.7. HRMS-ESI m/z [M + H]+ calc. for 
C21H28ClN2O+ 359.1890; found 359.1876. 
1-(Benzo[d][1,3]dioxol-5-yl)-N-((1-(2-chlorobenzyl)piperidin-4-yl)methyl)methanamine (19). 
The general procedure C was followed using 2 (0.200 g, 0.83 mmol) and benzo[d][1,3]dioxole-5-
carbaldehyde (0.120 g, 0.79 mmol), Na2SO4 (0.67 g, 4.72 mmol), DCM (10 mL) and a reaction time 
of 52 h. Imine reduction was performed with NaBH4 (0.045 g, 1.19 mmol), MeOH (10 mL) and 
reaction time of 30 min. Compound 19 was obtained as a yellow oil (0.250 g, 84%). 1H NMR (500 
MHz, CDCl3) δ 7.47 (dd, J = 7.6, 1.7 Hz, 1H), 7.33 (dd, J = 7.8, 1.3 Hz, 1H), 7.22 (td, J = 7.5, 1.4 
Hz, 1H), 7.16 (td, J = 7.6, 1.8 Hz, 1H), 6.83 (d, J = 1.2 Hz, 1H), 6.75 (d, J = 1.0 Hz, 2H), 5.93 (s, 
2H), 3.68 (s, 2H), 3.59 (s, 2H), 2.91 (app d, J = 11.9 Hz, 2H), 2.49 (d, J = 6.7 Hz, 2H), 2.06 (app t, J 
= 11.7 Hz, 2H), 1.75–1.66 (m, 2H), 1.54–1.44 (m, 2H), 1.32–1.23 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ 147.8, 146.5, 136.6, 134.7, 134.3, 130.7, 129.4, 128.0, 126.7, 121.2, 108.7, 108.2, 101.0, 
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59.7, 55.3, 54.0, 53.9, 36.3, 30.8. HRMS-ESI m/z [M + H]+ calc. for C21H26ClN2O2+ 373.1677; found 
373.1670. 
4-((((1-(2-Chlorobenzyl)piperidin-4-yl)methyl)amino)methyl)phenol (20). The general procedure 
C was followed using 2 (0.160 g, 0.65 mmol) and 4-hydroxybenzaldehyde (0.079 g, 0.65 mmol), 
Na2SO4 (0.554 g, 3.90 mmol), DCM (10 mL) and a reaction time of 44 h. Imine reduction was 
performed with NaBH4 (0.034 g, 0.91 mmol), MeOH (10 mL) and reaction time of 30 min. 
Compound 20 was obtained as a white solid (0.204 g, 91%). Mp: 89.7–94.7 oC. 1H NMR (500 MHz, 
CDCl3) δ 7.46 (d, J = 7.5 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.24–7.14 (m, 2H), 7.09 (d, J = 8.1 Hz, 
2H), 6.63 (d, J = 7.4 Hz, 2H), 3.68 (s, 2H), 3.60 (s, 2H), 2.92 (app d, J = 11.5 Hz, 2H), 2.65–2.34 
(m, 4H), 2.07 (app t, J = 10.8 Hz, 2H), 1.70 (app d, J = 12.2 Hz, 2H), 1.63–1.48 (m, 1H), 1.27 (qd, J 
= 12.2, 3.9 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 155.5, 136.1, 134.4, 131.1, 131.0, 129.7, 129.5, 
128.2, 126.7, 115.7, 59.6, 55.2, 53.8, 53.6, 35.8, 30.6. HRMS-ESI m/z [M + H]+ calc. for 
C20H26ClN2O+ 345.1734; found 345.1721.  
N-(4-Chlorobenzyl)-1-(1-(2-chlorobenzyl)piperidin-4-yl)methanamine (23). The general 
procedure C was followed using 2 (0.167 g, 0.70 mmol) and 4-chlorobenzaldehyde (0.098 g, 0.70 
mmol), Na2SO4 (0.597 g, 4.20 mmol), DCM (12 mL) and a reaction time of 29 h. Imine reduction 
was performed with NaBH4 (0.037 g, 0.98 mmol), MeOH (12 mL) and reaction time of 30 min. 
Compound 23 was obtained as a yellow oil (0.185 g, 73%). 1H NMR (500 MHz, CDCl3) δ 7.47 (d, J 
= 7.5 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.31–7.20 (m, 5H), 7.17 (t, J = 7.6 Hz, 1H), 3.74 (s, 2H), 
3.59 (s, 2H), 2.91 (app d, J = 11.0 Hz, 2H), 2.49 (d, J = 6.6 Hz, 2H), 2.06 (app t, J = 11.7 Hz, 2H), 
1.71 (app d, J = 12.5 Hz, and br s, 3H, overlapping), 1.55–1.42 (m, 1H), 1.27 (qd, J = 12.2, 3.7 Hz, 
2H). 13C NMR (126 MHz, CDCl3) δ 138.9, 136.4, 134.3, 130.8, 129.5, 129.4, 128.6, 128.1, 126.7, 
59.6, 55.3, 53.9, 53.4, 36.2, 30.7. HRMS-ESI m/z [M + H]+ calc. for C20H25Cl2N2+ 363.1395; found 
363.1383. 
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1-(1-(2-Chlorobenzyl)piperidin-4-yl)-N-(4-methylbenzyl)methanamine (24). The general 
procedure C was followed using 2 (0.155 g, 0.65 mmol) and 4-methylbenzaldehyde (0.078 g, 0.65 
mmol), Na2SO4 (0.554 g, 3.90 mmol), DCM (12 mL) and a reaction time of 65 h. Imine reduction 
was performed with NaBH4 (0.034 g, 0.91 mmol), MeOH (12 mL) and reaction time of 25 min. 
Compound 24 was obtained as a yellow oil (0.150 g, 67%). 1H NMR (500 MHz, CDCl3) δ 7.48 (d, J 
= 7.2 Hz, 1H), 7.34 (d, J = 7.8 Hz, 1H), 7.25 – 7.12 (m, 6H), 3.76 (s, 2H), 3.59 (s, 2H), 2.92 (app d, 
J = 11.6 Hz, 2H), 2.52 (d, J = 6.7 Hz, 2H), 2.34 (s, 3H), 2.06 (app t, J = 11.3 Hz, and br s, 3H), 1.72 
(app d, J = 12.5 Hz, 2H), 1.59 – 1.47 (m, 1H), 1.28 (qd, J = 12.2, 3.8 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 137.0, 136.6, 136.5, 134.2, 130.7, 129.4, 129.2, 128.2, 128.0, 126.6, 59.6, 55.2, 53.8, 53.8, 
36.0, 30.7, 21.2. HRMS-ESI m/z [M + H]+ calc. for C21H28ClN2+ 343.1941; found 343.1923. 
N-(2-Chlorobenzyl)-1-(1-(2-chlorobenzyl)piperidin-4-yl)methanamine (25). The general 
procedure C was followed using 2 (0.203 g, 0.85 mmol) and 2-chlorobenzaldehyde (0.119 g, 0.85 
mmol), Na2SO4 (0.724 g, 5.10 mmol), DCM (12 mL) and a reaction time of 25 h. Imine reduction 
was performed with NaBH4 (0.045 g, 1.19 mmol), MeOH (12 mL) and reaction time of 30 min. 
Compound 25 was obtained as a yellow oil (0.235 g, 76%). 1H NMR (500 MHz, CDCl3) δ 7.48 (d, J 
= 7.6 Hz, 1H), 7.38 (dd, J = 7.4, 1.8 Hz, 1H), 7.34 (t, J = 8.1 Hz, 2H), 7.25–7.14 (m, 4H), 3.87 (s, 
2H), 3.59 (s, 2H), 2.91 (app d, J = 11.1 Hz, 2H), 2.51 (d, J = 6.4 Hz, 2H), 2.07 (app t, J = 11.8, 2.5 
Hz, 2H), 1.77–1.68 (m, 2H), 1.61 (s, 1H), 1.56–1.45 (m, 1H), 1.31–1.22 (m, 2H).13C NMR (126 
MHz, CDCl3) δ 137.7, 134.3, 133.9, 133.8, 130.8, 130.3, 129.6, 129.4, 128.4, 128.1, 126.9, 126.7, 
59.6, 55.3, 53.9, 51.7, 36.2 30.7. HRMS-ESI m/z [M + H]+ calc. for C20H25Cl2N2+ 363.1395; found 
363.1374. 
1-(1-(2-Chlorobenzyl)piperidin-4-yl)-N-(2-methylbenzyl)methanamine (26). The general 
procedure C was followed using 2 (0.167 g, 0.70 mmol) and 2-methylbenzaldehyde (0.084 g, 0.70 
mmol), Na2SO4 (0.597 g, 4.20 mmol), DCM (12 mL) and a reaction time of 65 h. Imine reduction 
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was performed with NaBH4 (0.037 g, 0.98 mmol), MeOH (12 mL) and reaction time of 30 min. 
Compound 26 was obtained as a yellow oil (0.206 g, 86%). 1H NMR (500 MHz, CDCl3) δ 7.49 (d, J 
= 7.5 Hz, 1H), 7.34 (d, J = 7.8 Hz, 1H), 7.32 – 7.27 (m, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.21 – 7.12 
(m, 4H), 3.76 (s, 2H), 3.60 (s, 2H), 2.93 (app d, J = 11.4 Hz, 2H), 2.57 (d, J = 6.6 Hz, 2H), 2.35 (s, 
3H), 2.08 (app t, J = 11.8 Hz, 2H), 1.74 (app d, J = 10.4 Hz, 2H), 1.64 – 1.40 (m, 2H), 1.30 (app q, J 
= 12.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 138.4, 136.4, 136.4, 134.3, 130.7, 130.4, 129.4, 
128.3, 128.0, 127.0, 126.7, 126.0, 59.7, 55.9, 53.9, 51.9, 36.2, 30.8, 19.1. HRMS-ESI m/z [M + H]+ 
calc. for C21H28ClN2+ 343.1941; found 343.1930.  
1-(1-(2-Chlorobenzyl)piperidin-4-yl)-N-(3-methylbenzyl)methanamine (28). The general 
procedure C was followed using 2 (0.179 g, 0.75 mmol) and 3-methylbenzaldehyde (0.090 g, 0.75 
mmol), Na2SO4 (0.639 g, 4.50 mmol), DCM (12 mL) and a reaction time of 41 h. Imine reduction 
was performed with NaBH4 (0.040 g, 1.05 mmol), MeOH (12 mL) and reaction time of 30 min. 
Compound 28 was obtained as a yellow oil (0.212 g, 82%). 1H NMR (500 MHz, CDCl3) δ 7.48 (d, J 
= 7.5 Hz, 1H), 7.34 (d, J = 7.9 Hz, 1H), 7.27–7.20 (m, 2H), 7.20–7.10 (m, 3H), 7.08 (d, J = 7.5 Hz, 
1H), 3.76 (s, 2H), 3.60 (s, 2H), 2.92 (app d, J = 11.1 Hz, 2H), 2.53 (d, J = 6.6 Hz, 2H), 2.36 (s, 3H), 
2.07 (app t, J = 11.7 Hz, 2H), 1.92 (br s, 1H), 1.73 (app d, J = 12.5 Hz, 2H), 1.61–1.46 (m, 1H), 1.29 
(qd, J = 12.3, 3.8 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 140.2, 138.1, 136.4, 134.2, 130.7, 129.4, 
129.00, 128.4, 128.0, 127.8, 126.6, 125.2, 59.6, 55.4, 54.1, 53.9, 36.1, 30.7, 21.5. HRMS-ESI m/z [M 
+ H]+ calc. for C21H28ClN2+ 343.1941; found 343.1929. 
1-(1-(3-Chlorobenzyl)piperidin-4-yl)-N-(3-methylbenzyl)methanamine (29). The general 
procedure C was followed using 7j (0.119 g, 0.50 mmol) and 3-methylbenzaldehyde (0.060 g, 0.83 
mmol), Na2SO4 (0.426 g, 3.00 mmol), DCM (10 mL) and a reaction time of 47 h. Imine reduction 
was performed with NaBH4 (0.026 g, 0.70 mmol), MeOH (7 mL) and reaction time of 30 min. 
Compound 29 was obtained as a yellow oil (0.115 g, 67%). 1H NMR (500 MHz, CDCl3) δ 7.32 (s, 
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1H), 7.25–7.16 (m, 4H), 7.13 (s, 1H), 7.11 (d, J = 7.6 Hz, 1H), 7.06 (d, J = 7.5 Hz, 1H), 3.74 (s, 2H), 
3.44 (s, 2H), 2.86 (app d, J = 11.4 Hz, 2H), 2.52 (d, J = 6.7 Hz, 2H), 2.34 (s, 3H), 1.95 (app t, J = 
10.9 Hz, 2H), 1.71 (app d, J = 12.5 Hz, 2H), 1.60 (s, 1H), 1.55–1.45 (m, 1H), 1.26 (qd, J = 12.2, 3.9 
Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 141.0, 140.0, 138.2, 134.2, 129.5, 129.15, 129.0, 128.4, 
127.9, 127.3, 127.2, 125.3, 63.0, 55.3, 54.1, 53.8, 36.1, 30.7, 21.5. HRMS-ESI m/z [M + H]+ calc. for 
C21H28ClN2+ 343.1941; found 343.1938.  
1-(1-(4-Chlorobenzyl)piperidin-4-yl)-N-(3-methylbenzyl)methanamine (30). The general 
procedure C was followed using 7i (0.119 g, 0.50 mmol) and 3-methylbenzaldehyde (0.060 g, 0.83 
mmol), Na2SO4 (0.426 g, 3.00 mmol), DCM (10 mL) and a reaction time of 3 days. Imine reduction 
was performed with NaBH4 (0.026 g, 0.70 mmol), MeOH (7 mL) and reaction time of 15 min. 
Compound 30 was obtained as a yellow oil (0.141 g, 82%). 1H NMR (500 MHz, CDCl3) δ 7.33–7.23 
(m, 4H), 7.21 (d, J = 7.5 Hz, 1H), 7.14 (s, 1H), 7.11 (d, J = 7.7 Hz, 1H), 7.07 (d, J = 7.6 Hz, 1H), 
3.75 (s, 2H), 3.44 (s, 2H), 2.86 (app d, J = 11.1 Hz, 2H), 2.52 (d, J = 6.7 Hz, 2H), 2.35 (s, 3H), 1.94 
(app t, J = 11.6 Hz, 2H), 1.71 (d, J = 12.6 Hz, 2H), 1.57–1.39 (m, 2H), 1.31–1.21 (m, 2H). 13C NMR 
(126 MHz, CDCl3) δ 140.5, 138.1, 137.3, 132.6, 130.5, 128.9, 128.4, 127.7, 125.2, 62.8, 55.6, 54.3, 
53.8, 36.3, 30.7, 21.5. HRMS-ESI m/z [M + H]+ calc. for C21H28ClN2+ 343.1941; found 343.1920.  
1-(1-(2,3-Dichlorobenzyl)piperidin-4-yl)-N-(3-methylbenzyl)methanamine (31). The general 
procedure C was followed using 7k (0.137 g, 0.50 mmol) and 3-methylbenzaldehyde (0.060 g, 0.50 
mmol), Na2SO4 (0.426 g, 3.00 mmol), DCM (10 mL) and a reaction time of 3 days. Imine reduction 
was performed with NaBH4 (0.026 g, 0.70 mmol), MeOH (7 mL) and reaction time of 15 min. 
Compound 31 was obtained as a yellow oil (0.128 g, 68%). 1H NMR (500 MHz, CDCl3) δ 7.41 (d, J 
= 7.7 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 7.17 (t, J = 7.8 Hz, 1H), 7.13 (s, 
1H), 7.10 (d, J = 7.6 Hz, 1H), 7.06 (d, J = 7.6 Hz, 1H), 3.74 (s, 2H), 3.60 (s, 2H), 2.89 (app d, J = 
11.7 Hz, 2H), 2.52 (d, J = 6.6 Hz, 2H), 2.35 (s, 3H), 2.08 (app t, J = 11.6 Hz, 2H), 1.72 (app d, J = 
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12.5 Hz, 2H), 1.59–1.40 (m, 2H), 1.28 (qd, J = 12.2, 3.9 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 
140.5, 139.2, 138.1, 133.00, 132.3, 129.00, 128.7, 128.5, 128.41, 127.8, 127.0, 125.2, 60.4, 55.6, 
54.3, 54.0, 36.2, 30.80, 21.6. HRMS-ESI m/z [M + H]+ calc. for C21H27Cl2N2+ 377.1551; found 
377.1540. 
(1-(2,3-Dichlorobenzyl)piperidin-4-yl)methanamine (32). The general procedure C was followed 
using 7l (0.123 g, 0.45 mmol) and 3-methylbenzaldehyde (0.054 g, 0.45 mmol), Na2SO4 (0.384 g, 
2.70 mmol), DCM (10 mL) and a reaction time of 27 h. Imine reduction was performed with NaBH4 
(0.024 g, 0.63 mmol), MeOH (7 mL) and reaction time of 15 min. Compound 32 was obtained as a 
yellow oil (0.100 g, 59%). 1H NMR (500 MHz, CDCl3) δ 7.28 (d, J = 8.0 Hz, 2H), 7.20 (t, J = 7.5 
Hz, 1H), 7.14–7.11 (m, 2H), 7.09 (d, J = 7.3 Hz, 1H), 7.05 (d, J = 7.6 Hz, 1H), 3.73 (s, 2H), 3.70 (s, 
2H), 2.91 (app d, J = 11.3 Hz, 2H), 2.48 (d, J = 6.8 Hz, 2H), 2.34 (s, 3H), 2.18 (app t, J = 11.6 Hz, 
2H), 1.73–1.64 (m, 3H), 1.56–1.44 (m, 1H), 1.20 (qd, J = 12.2, 3.9 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 140.4, 138.1, 137.1, 135.0, 129.0, 128.7, 128.4, 128.4, 127.8, 125.2, 57.0, 55.5, 54.2, 53.8, 
36.1, 30.7, 21.5. HRMS-ESI m/z [M + H]+ calc. for C21H27Cl2N2+ 377.1551; found 377.1537.  
1-(1-(2-Chlorobenzyl)piperidin-4-yl)-N-(naphthalen-2-ylmethyl)methanamine fumarate (21). 
The general procedure C was followed using 2 (0.119 g, 0.50 mmol) and 1-naphtaldehyde (0.078 g, 
0.50 mmol), Na2SO4 (0.426 g, 3.00 mmol), DCM (12 mL) and a reaction time of 3 days. Imine 
reduction was performed with NaBH4 (0.027 g, 0.70 mmol), MeOH (12 mL) and reaction time of 20 
min, furnishing crude 1-(1-(2-chlorobenzyl)piperidin-4-yl)-N-(naphthalen-2-ylmethyl)methanamine 
(free amine) containing 1-naphtaldehyde impurity as determined by NMR and HPLC. To a solution 
of this crude product (0.124 g, 93% pure) in 2-PrOH (10 mL), a solution of fumaric acid (0.076 g, 
0.65 mmol, theoretically 2.0 eq) in 2-PrOH (5 mL) was added. The mixture was stirred at rt for 1 h. 
Next, the mixture was cooled in an ice bath for 1 h. The precipitate formed was filtered, washed with 
excess of EtOAc and extensively dried overnight in a vacuum oven at 40 0C. This afforded salt 21 as 
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a white solid (0.153 g, overall yield 52%), which contains 1.785 eq fumarate as a salt and is a 2-
PrOH solvate (0.1 eq) as determined by NMR analysis. Mp: 202.5–206.9 oC. 1H NMR (500 MHz, 
DMSO-d6) δ 7.91 (tt, J = 9.2, 3.9 Hz, 4H), 7.60–7.55 (m, 1H), 7.56–7.49 (m, 2H), 7.46 (dd, J = 7.6, 
1.8 Hz, 1H), 7.41 (dd, J = 7.8, 1.5 Hz, 1H), 7.31 (td, J = 7.5, 1.5 Hz, 1H), 7.27 (td, J = 7.6, 1.9 Hz, 
1H), 6.56 (s, 3.57H (fumarate)), 4.09 (d, J = 9.3 Hz, 2H), 3.52 (s, 2H), 2.81 (app d, J = 11.8 Hz, 2H), 
2.67–2.60 (m, 2H), 2.00 (app t, J = 11.7, 2.4 Hz, 2H), 1.72 (app d, J = 12.4 Hz, 2H), 1.59 (s, 1H), 
1.17 (qd, J = 12.2, 3.8 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 167.1, 135.7, 134.7, 133.3, 132.7, 
132.6, 131.1, 130.8, 129.3, 129.0, 128.6, 128.1, 127.8, 127.7, 127.2, 127.0, 126.6, 58.8, 52.7, 51.9, 
50.8, 33.1, 29.5. HRMS-ESI m/z [M + H]+ calc. for C24H28ClN2+ 379.1941; found 379.1937. 
1-([1,1'-Biphenyl]-3-yl)-N-((1-(2-chlorobenzyl)piperidin-4-yl)methyl)methanamine fumarate 
(22). The general procedure C was followed using 2 (0.119 g, 0.50 mmol), [1,1'-biphenyl]-3-
carbaldehyde (0.091 g, 0.50 mmol), Na2SO4 (0.426 g, 3.00 mmol), DCM (12 mL) and a reaction 
time of 50 h. Imine reduction was performed with NaBH4 (0.027 g, 0.70 mmol), MeOH (12 mL) and 
reaction time of 20 min, furnishing crude 1-([1,1'-biphenyl]-3-yl)-N-((1-(2-chlorobenzyl)piperidin-4-
yl)methyl)methanamine (0.155 g, 90% pure). Compound 22 was prepared as described for 
compound 21 using corresponding crude amine (0.122 g) in 2-PrOH (10 mL), a solution of fumaric 
acid (0.070 g, 0.60 mmol, theoretically 2.0 eq) in 2-PrOH (5 mL) and salt formation time 3 h. 
Compound 22 was obtained as a white solid (0.147 g, overall yield 47%), containing 1.850 eq 
fumarate as a salt and is a 2-PrOH solvate (0.08 eq) as determined by NMR analysis. Mp: 189.9–
193.4 oC. 1H NMR (500 MHz, DMSO-d6) δ 7.78 (br s, 1H), 7.69–7.65 (m, 2H), 7.63 (d, J = 7.2 Hz, 
1H), 7.51–7.44 (m, 4H), 7.44–7.35 (m, 3H), 7.34-7.29 (m, 1H), 7.29-7.24 (m, 1H), 6.56 (s, 3.70H 
(fumarate)), 4.03 (s, 2H), 3.52 (s, 2H), 2.81 (app d, J = 11.4 Hz, 2H), 2.68 (br s, 2H), 2.04–1.96 (m, 
2H), 1.72 (app d, J = 12.4 Hz, 2H), 1.61 (br s, 1H), 1.18 (qd, J =12.1, 3.7 Hz, 2H). 13C NMR (126 
MHz, DMSO-d6) δ 167.0, 140.3, 139.7, 135.8, 134.6, 134.3, 133.3, 130.8, 129.2, 129.1, 129.0, 
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128.8, 128.6, 128.2, 127.7, 127.0, 126.7, 126.6, 58.8, 52.7, 52.1, 50.8, 33.1, 29.6. HRMS-ESI m/z [M 
+ H]+ calc. for C26H31ClN2+ 405.2098; found 379.1937. 
N-(3-Chlorobenzyl)-1-(1-(2-chlorobenzyl)piperidin-4-yl)methanamine fumarate (27). The 
general procedure C was followed using 2 (0.155 g, 0.65 mmol), 3-chlorobenzaldehyde (0.091 g, 
0.65 mmol), Na2SO4 (0.554 g, 3.90 mmol), DCM (12 mL) and a reaction time of 69 h. Imine 
reduction was performed with NaBH4 (0.034 g, 0.91 mmol), MeOH (12 mL) and reaction time of 30 
min, furnishing N-(3-chlorobenzyl)-1-(1-(2-chlorobenzyl)piperidin-4-yl)methanamine (0.185 g, 97% 
pure, 67% yield). Compound 27 was prepared as described for compound 21 using corresponding 
amine (0.067 g) in 2-PrOH (5 mL), a solution of fumaric acid (0.043 g, 0.60 mmol, theoretically 2.0 
eq) in 2-PrOH (2 mL) and salt formation time 2 h. Compound 27 was obtained as a white solid 
(0.062 g, overall yield 38%), containing 1.875 eq fumarate as a salt and is a 2-PrOH solvate (0.04 eq) 
as determined by NMR analysis. Mp: 212.4–220.1 oC.  1H NMR (600 MHz, DMSO-d6) δ 7.53 (s, 
1H), 7.46 (d, J = 7.3 Hz, 1H), 7.44–7.34 (m, 4H), 7.32 (t, J = 7.2 Hz, 1H), 7.27 (t, J = 7.5 Hz, 1H), 
6.57 (s, 3.75H (fumarate)), 3.93 (s, 2H), 3.53 (s, 2H), 2.81 (app d, J = 11.4 Hz, 2H), 2.60 (d, J = 6.7 
Hz, 2H), 2.01 (app t, J = 11.9 Hz, 2H), 1.70 (app d, J = 14.4 Hz, 2H), 1.63–1.53 (m, 1H), 1.17 (qd, J 
= 12.3, 3.8 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 166.6, 138.7, 135.8, 134.4, 133.2, 133.0, 
130.7, 130.2, 129.2, 128.8, 128.5, 127.7, 127.7, 127.0, 58.8, 52.0, 52.9, 50.9, 34.0, 29.8. HRMS-ESI 
m/z [M + H]+ calc. for C20H25Cl2N2+ 363.1395; found 363.1373. 
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Fig. S1. The 23 structure-based virtual screening hits. The dashed line indicates four fragment hits 
selected based on a single concentration (63 µM) screening on 125I-CXCL12 displacement in 
HEK293T-CXCR4 membranes. After visual and validation selection, EN300-71537 (2) has been 
selected as the lead fragment with its core scaffold depicted in blue. 
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Fig. S2. Details of MD simulations on two binding modes of compound 28. (A) and (C) show the 
two alternative docking poses of compound 28, which is shown in pink stick in Model 1 and in 
magenta stick in Model 2, respectively. The refined binding poses (cyan and green) after MD 
simulations are aligned with their initial pose (in transparent stick) and are shown in (B) and (D). 
Important binding residues are depicted as sticks with grey carbon atoms. Oxygen, nitrogen, and 
hydrogen atoms are colored red, blue and white, respectively. H-bonds described in the text are 
depicted by dashed lines. 
  
66 
 
Table S1 
Inhibition of 125I-CXCL12 and CXCL12-red binding to CXCR4 by key antagonists  
 
Compounds 
125I-CXCL12 bindinga 
BRET CXCL12-red 
bindingb 
pIC50 % displacement pIC50 % displacement 
 13 6.5 ± 0.1 87 ± 4 6.1 ± 0.0 84 ± 2 
22 6.3 ± 0.0 98 ± 1  6.2 ± 0.0 98 ± 0 
28 6.8 ± 0.1 63 ± 1  6.0 ± 0.1 73 ± 3 
IT1t 8.0 ± 0.0 100 ± 2  8.0 ± 0.0 100 ± 0  
 
a Measured as competition of 125I-CXCL12 (50 pM) binding to hCXCR4 expressed in membranes of transiently 
transfected HEK293T cells. pIC50 values are means ± SEM (N = 3 (for compound 13: N = 9) with each experiment 
performed in triplicate). Percentage of the displacement of 125I-CXCL12 (50 pM) in a presence of the ligand (100 µM) is 
relative to IT1t (100 µM, 100 %). 
b Results are expressed as percentage of inhibition of CXCL12-red binding (25 nM) to NLuc-tagged CXCR4  
(N = 3 with each experiment performed in triplicate). Normalized to 0% = buffer and 100% = IT1t at 10 µM.  
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Fig. S3. HPLC/MS chromatogram of compound 13 
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Fig. S4. 1H NMR spectrum (CDCl3) of compound 13 
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Fig. 
S5. 13C NMR spectrum (CDCl3) of compound 13 
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Fig. S6. HPLC/MS chromatogram of compound 28 
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Fig. S7. 1H NMR spectrum (CDCl3) of compound 28 
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Fig. S8. 13C NMR spectrum (CDCl3).of compound 28 
 
73 
 
 
Fig. S9. HPLC/MS chromatogram of compound 22 
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Fig. S10. 1H NMR spectrum (DMSO-d6) of compound 22 
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Fig. S11. 13C NMR spectrum (DMSO-d6) of compound 22 
 
 
